Skip to content
OTC Biotech
  • Home
  • Contact
  • About
    • Privacy Policy

Game-Changer: FDA Grants Approval to TOFIDENCE™, a Biosimilar of ACTEMRA® by Bio-Thera Solutions

October 9, 2023 by Allen Williams

Bio-Thera Solutions, Ltd. has announced that its partner, Biogen, received FDA approval for TOFIDENCE (tocilizumab-bavi), an intravenous formulation biosimilar referencing ACTEMRA. This marks Bio-Thera’s first … Read more

Harmonic Bionics Revolutionizes Rehabilitation: First Harmony SHR™ Robotic System Installed at Leading Neurological Hospital in Phoenix

October 9, 2023 by Allen Williams

Harmonic Bionics has announced that Barrow Neurological Institute in Phoenix, Arizona, has acquired two Harmony SHR™ exoskeletons for use in both inpatient and outpatient programs. … Read more

Sigrid Therapeutics Breaks New Ground: SiPore21® Medical Device Successfully Treats First Patient, Paving the Way for Diabetes and Obesity Control

October 9, 2023 by Allen Williams

Sigrid Therapeutics has initiated the SHINE clinical trial for SiPore21®, a novel medical device designed for sustained diabetes and weight control. SiPore21® is based on … Read more

Groundbreaking Milestone: Atom Bioscience Administers First Dose in Phase 2b/3 Clinical Trial for Cutting-Edge Chronic Gout Treatment

October 9, 2023 by Allen Williams

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical-stage biotechnology company, has announced the dosing of the first patient in a Phase 2b/3 … Read more

Mark Your Calendars: Exact Sciences Sets the Stage for an Exciting Q3 2023 Earnings Call

October 9, 2023 by Allen Williams

Exact Sciences Corp. (Nasdaq: EXAS), a prominent provider of cancer screening and diagnostic tests, has scheduled the release of its third-quarter 2023 financial results for … Read more

QHP Capital’s Strategic Move: Acquiring Applied StemCell for Future Growth

October 9, 2023 by Allen Williams

QHP Capital has announced its acquisition of Applied StemCell, Inc. (ASC), a cell and gene therapy Contract Research Organization (CRO) and Contract Development and Manufacturing … Read more

Remarkable: Six Drugs Secured Approval Against All Odds, Defying Failed Trials and Sparse Data

October 9, 2023 by Allen Williams

The FDA’s recent approvals of certain novel drugs despite failed clinical trials or limited evidence have sparked a debate about whether the agency is moving … Read more

Revolutionary RNA Editing Therapy Inches Closer to Clinical Reality, Igniting Enthusiasm

October 9, 2023 by Allen Williams

Wave Life Sciences is making waves in the field of RNA editing therapy with its recent submission of a clinical trial application for WVE-006, a … Read more

Novartis Scores FDA Green Light for Game-Changing Intravenous Version of Cosentyx

October 9, 2023 by Allen Williams

In a significant development, the FDA gave its green light on Friday to an intravenous version of Novartis’ IL-17A antagonist, Cosentyx (secukinumab), for the treatment … Read more

BMS Makes a Bold Move: Acquires Mirati for $4.8 Billion, Supercharging Their Cancer Portfolio

October 9, 2023 by Allen Williams

Exciting news broke on Sunday as Bristol Myers Squibb (BMS) unveiled a groundbreaking merger agreement with the cancer-focused biotech company, Mirati Therapeutics. The aim? To … Read more

Verona Pharma Sets the Stage for Ensifentrine’s Commercialization with Investor Update on October 18, 2023

October 6, 2023 by Allen Williams

Verona Pharma is scheduled to hold an Investor Update event in New York City on October 18, 2023, from 8:00 AM to 10:00 AM ET. … Read more

FDA Bestows Orphan Drug Designation on GC Biopharma’s Promising Treatment for Thrombotic Thrombocytopenic Purpura

October 6, 2023 by Allen Williams

GC Biopharma Corp. announced that its drug candidate, GC1126A, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment … Read more

Purple Biotech Unveils Encouraging Biomarker Data Reinforcing CM24’s Mechanism of Action

October 6, 2023 by Allen Williams

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage biotechnology company focused on developing first-in-class therapies designed to harness the potential of the tumor microenvironment. The … Read more

IDEAYA Biosciences Reveals Exciting Inducement Grants Pursuant to Nasdaq Listing Rule 5635(c)(4) – October 06, 2023

October 6, 2023 by Allen Williams

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company specializing in the discovery and development of targeted therapeutics, has announced that the Compensation Committee … Read more

Asceneuron Names Barbara Angehrn Pavik as CEO to Lead Next Phase of Thrilling Growth

October 6, 2023 by Allen Williams

Asceneuron SA, a clinical-stage company focused on targeting the root causes of neurodegenerative diseases, has appointed Barbara Angehrn Pavik as its new Chief Executive Officer … Read more

Aktivolabs Achieves HIPAA Certification, Marks Grand Entry into the U.S. Market

October 6, 2023 by Allen Williams

Aktivolabs, a digital health science company, has announced its HIPAA compliance and the launch of its operations in the United States. The company’s mission is … Read more

FDA Greenlights Arcutis’ ZORYVE® Cream 0.3% for Pediatric Psoriasis Treatment in Children Aged 6 to 11

October 6, 2023 by Allen Williams

Arcutis Biotherapeutics, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) to expand the indication … Read more

Locanabio Unveils Promising Preclinical Data Showcasing Advancements in snRNA Platform

October 6, 2023 by Allen Williams

Locanabio, a genetic medicines company dedicated to developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, has unveiled groundbreaking data showcasing the … Read more

Keytruda by Merck Sets Sights on Bladder Cancer Breakthrough with Exciting Phase III Results

October 6, 2023 by Allen Williams

Merck has reported a significant breakthrough in its Phase III AMBASSADOR trial involving the blockbuster PD-1 inhibitor, Keytruda (pembrolizumab), for the treatment of muscle-invasive urothelial … Read more

Amgen’s Lumakras Faces FDA Hurdle as Advisory Committee Withholds Full Support

October 6, 2023 by Allen Williams

In a dramatic showdown at the FDA’s Oncologic Drugs Advisory Committee, Amgen’s hopes of elevating its oral G12C KRAS inhibitor, Lumakras, from accelerated approval to … Read more

Unexpected Twist: Avertix and BIOS Acquisition Corporation Unanimously Decide to Call Off Planned Business Merger

October 5, 2023 by Allen Williams

Avertix Medical, Inc., formerly known as Angel Medical Systems, Inc., and BIOS Acquisition Corporation have mutually agreed to terminate their proposed business combination. The decision … Read more

ZyVersa Therapeutics Unveils Cutting-Edge Research: Peer-Reviewed Publication Strengthens Case for IC 100 in Halting Inflammation’s Reach into Nearby Tissues

October 5, 2023 by Allen Williams

ZyVersa Therapeutics, a cutting-edge biopharmaceutical company focused on developing groundbreaking drugs for inflammatory and renal diseases, has published a groundbreaking scientific paper in the esteemed … Read more

AI Proteins Gains a Renowned Expert: Dr. Robert Stein Joins the Ranks of its Scientific Advisory Board

October 5, 2023 by Allen Williams

AI Proteins, Inc., a biotechnology company specializing in computational de novo protein design for therapeutic miniproteins, has appointed Dr. Robert Stein, MD, PhD, to its … Read more

Groundbreaking Insights: Calliditas Unveils Fresh Findings from NefIgArd Phase 3 Trial at Tokyo 2023 Symposium on IgA Nephropathy

October 5, 2023 by Allen Williams

Everest Medicines and its partner Calliditas Therapeutics have presented new biomarker and subgroup analyses from the Phase 3 NefIgArd study of Nefecon® at the 17th … Read more

CRISPR Collaboration Takes a Bold Leap: Regeneron and Intellia Join Forces to Tackle Neurological and Muscular Disorders

October 5, 2023 by Allen Williams

Regeneron has announced an expansion of its collaboration agreement with Intellia Therapeutics to develop CRISPR-based gene editing therapies targeting neurological and muscular diseases. The expanded … Read more

Vertex’s Breakthrough: Remarkable Results Revealed for Stem Cell-Based Type 1 Diabetes Therapy

October 5, 2023 by Allen Williams

Vertex Pharmaceuticals has unveiled promising longer-term results from parts A and B of its Phase I/II trial for the investigational stem cell-derived therapy VX-880, which … Read more

Big Pharma Showdown: Ten Industry Giants Enroll for Medicare Drug Price Negotiation Program

October 5, 2023 by Allen Williams

In a significant development, all 10 pharmaceutical companies whose products were chosen for the initial round of Medicare drug price negotiations have agreed to participate … Read more

FDA Exposes ‘Systemic Bias’ in Amgen’s Lumakras Trial as Adcomm Meeting Looms

October 5, 2023 by Allen Williams

Amgen’s hopes for gaining full approval for its non-small cell lung cancer drug, Lumakras (sotorasib), encountered a significant setback as FDA staff expressed concerns about … Read more

Sanofi and Teva Seal Mega $1.5 Billion Pact to Unlock Potential Blockbuster IBD Medication

October 5, 2023 by Allen Williams

In a bold move that could challenge industry giants like Merck and Pfizer, French pharmaceutical powerhouse Sanofi made waves on Wednesday by announcing a strategic … Read more

Pharma Titans Unite: Powerful Coalition Emerges to Battle FTC’s Antitrust Overhaul

October 5, 2023 by Allen Williams

In a bold move, pharmaceutical giants, including AbbVie, Amgen, Gilead, Merck, and Novartis, have joined forces to create a formidable 31-member coalition known as the … Read more

Sandoz Ushers in a New Era: Emerging as a Standalone Global Pioneer and European Trailblazer in Generic and Biosimilar Medicines

October 4, 2023 by Allen Williams

Sandoz, a global leader in generic and biosimilar medicines, has begun trading its shares on the SIX Swiss Exchange as an independent company. The company … Read more

Skanska Secures USD 85M Deal to Expand Cancer Center in Livingston, New Jersey, USA – A Milestone Project Worth SEK 900M

October 4, 2023 by Allen Williams

Skanska, a construction company, has secured an additional contract from RWJBarnabas Health to build an ambulatory care cancer center in Livingston, New Jersey, USA. The … Read more

ViroCell Strengthens Its Ranks: Bolsters Business Development Team for an Exciting Phase of Growth Ahead

October 4, 2023 by Allen Williams

ViroCell Biologics, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy clinical trials, has appointed Traci Kyes as Vice President (VP) … Read more

Orakl Oncology Secures €3 Million to Fuel Cutting-Edge Techbio Platform Advancements in Precision Oncology

October 4, 2023 by Allen Williams

Orakl Oncology, a precision oncology startup, has announced a successful fundraising round of €3 million to advance its techbio platform. The platform integrates cutting-edge biology … Read more

Dignitana Forges a Scalp-Cooling Revolution: Strategic Sales and Marketing Partnership with InfuSystem in the United States

October 4, 2023 by Allen Williams

Dignitana AB, a pioneer in scalp cooling technology, has made an exciting announcement about a sales and marketing partnership with InfuSystem Holdings, Inc. InfuSystem is … Read more

Syndax’s Remarkable Leap: Leukemia Trial Halted Prematurely as Drug Triumphs, Meeting Primary Endpoint

October 4, 2023 by Allen Williams

Syndax Pharmaceuticals has unveiled encouraging topline data from its pooled analysis of the AUGMENT-101 trial, which assessed its menin inhibitor, revumenib, in adult and pediatric … Read more

Novartis Triumphs in Phase III for IgAN Treatment, Sets Sights on Regulatory Journey for Complement Inhibitor

October 4, 2023 by Allen Williams

Novartis has shared exciting news regarding its investigational complement inhibitor, iptacopan, in the Phase III APPLAUSE-IgAN study. While specific data details were not provided, Novartis … Read more

Boehringer Breaks New Ground, Unveiling Budget-Friendly Biosimilar at a Remarkable 81% Off AbbVie’s Humira

October 4, 2023 by Allen Williams

Boehringer Ingelheim has made a significant move in the healthcare landscape by introducing lower wholesale pricing for its adalimumab-adbm injection, an interchangeable biosimilar to AbbVie’s … Read more

Takeda’s Courageous Decision: Navigating Challenges as Lung Cancer Drug Falls Short in Confirmatory Trial

October 4, 2023 by Allen Williams

Takeda has taken a tough but necessary decision to withdraw its lung cancer drug, mobocertinib, known as Exkivity, from both U.S. and global markets. This … Read more

Lilly’s Bold Move: Supercharging its Oncology Arsenal with $1.4B Point Biopharma Acquisition

October 4, 2023 by Allen Williams

Eli Lilly is making a bold move to supercharge its cancer-fighting arsenal by announcing the acquisition of Point Biopharma. This Pennsylvania-based gem comes with a … Read more

Biohaven Sets the Stage with a $225 Million Public Offering: What Lies Ahead?

October 3, 2023 by Allen Williams

Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies for a wide range of rare and common … Read more

Hamilton Company Revolutionizes Dissolved Oxygen Sensing with VisiFerm™ SU: A Game-Changing Upgrade for Single-Use Applications

October 3, 2023 by Allen Williams

Hamilton Company, a leading provider of automation technology and analytical sensors, has unveiled the redesigned VisiFerm™ SU RS485-ECS, a solid-state optical dissolved oxygen (DO) sensor … Read more

Exciting News: Oxford BioTherapeutics’ Partner, Boehringer Ingelheim, Earns Fast Track Designation from U.S. FDA for Promising Cancer Treatment

October 3, 2023 by Allen Williams

Oxford BioTherapeutics (OBT), a clinical-stage oncology company specializing in immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, has announced that the U.S. Food and Drug Administration … Read more

Revelation Biosciences Welcomes Renowned Physician Lakhmir Chawla, M.D. to Its Board of Directors

October 3, 2023 by Allen Williams

Revelation Biosciences Inc. (NASDAQ: REVB), a life sciences company dedicated to developing immunologic-based therapies for disease prevention and treatment, has announced the appointment of Dr. … Read more

Galderma’s Momentum Grows: Exciting Developments in RelabotulinumtoxinA Regulatory Approvals

October 3, 2023 by Allen Williams

Galderma, a rising star in the dermatology sector, has provided an update on the regulatory front regarding its pending Biologics License Application (BLA) for RelabotulinumtoxinA … Read more

FDA on High Alert: Amgen, Alnylam, and BMS Await Regulatory Action

October 3, 2023 by Allen Williams

In the coming fortnight, the FDA is set to deliver critical decisions on several pivotal pharmaceuticals. Alnylam’s Onpattro for cardiomyopathy of ATTR and Bristol Myers … Read more

Structure Therapeutics’ Weight Loss Breakthrough Triumphs in Phase I, Sending Stock Soaring to New Heights

October 3, 2023 by Allen Williams

In a thrilling turn of events, San Francisco-based biotech powerhouse Structure Therapeutics experienced a meteoric rise in its shares, surging by an astonishing 70% during … Read more

Lexeo and Abivax Brave the IPO Waters on Nasdaq Amidst a Desert of Opportunities

October 3, 2023 by Allen Williams

In a dynamic move toward growth and innovation, genetic medicines biotech Lexeo Therapeutics and immune-focused French firm Abivax have taken the exciting step of filing … Read more

Federal Judge Upholds Medicare’s Bold Move: Drug Price Negotiation Program to Continue

October 3, 2023 by Allen Williams

In a legal showdown that had the healthcare industry on the edge of its seat, a federal court judge delivered a dramatic ruling on Friday. … Read more

FDA’s Surprise Rejection: Lilly’s Eczema Breakthrough Stumbles Due to Manufacturing Hurdles

October 3, 2023 by Allen Williams

Eli Lilly, a pharmaceutical giant, received a surprising setback when the FDA rejected its promising antibody, lebrikizumab, intended for the treatment of moderate-to-severe atopic dermatitis. … Read more

Powerhouse Partnership: Akeso and RemeGen Join Forces for Groundbreaking Clinical Study, Pioneering PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combo in Gastric Cancer Treatment

October 2, 2023 by Allen Williams

On September 28, 2023, Akeso (9926.HK) made an exciting announcement regarding its subsidiary, Akeso Pharma, which is set to collaborate with RemeGen (Yantai) Co., Ltd. … Read more

Macomics’ Bold Expansion: Embracing Roslin Innovation Centre in Edinburgh and Welcoming Professor Paul Crocker to the SAB

October 2, 2023 by Allen Williams

Macomics Ltd, a trailblazer in macrophage drug discovery, continues its impressive journey with an expansion into dedicated facilities at the Roslin Innovation Centre in Edinburgh. … Read more

Codexis Celebrates Triumph: CEO Stephen Dilly Honored with the Prestigious 2023 Bloom Burton Award

October 2, 2023 by Allen Williams

In a prestigious recognition of his outstanding contributions to the healthcare industry, Dr. Stephen Dilly, President and CEO of Codexis, Inc., has been awarded the … Read more

Synlogic’s Big Move: Exciting News as Company Prices $21.0 Million Underwritten Public Offering

October 2, 2023 by Allen Williams

Synlogic, Inc. (Nasdaq: SYBX) has just made a big move in the world of biotechnology. The company, which is on a mission to transform the … Read more

Microbix Takes Center Stage: Key Presentation at Muskoka Capital Conference – Mark Your Calendar for September 29, 2023!

October 2, 2023 by Allen Williams

Get ready for some exciting insights! Microbix Biosystems Inc., the trailblazing life sciences innovator, is set to dazzle at the Muskoka Capital Conference. From September … Read more

Breakthrough Discovery: Theralase(R) Unveils Remarkable 8-Year Shelf Life for Star Drug Ruvidar(TM)

October 2, 2023 by Allen Williams

Imagine a groundbreaking innovation that wields the power of light and radiation to combat cancer, bacteria, and viruses. Enter Theralase® Technologies Inc., a clinical stage … Read more

Thymmune Therapeutics Secures a Game-Changing $37M from ARPA-H to Revolutionize Healthcare

October 2, 2023 by Allen Williams

In a groundbreaking move, Thymmune Therapeutics, a biotech trailblazer, has received a significant financial boost from the U.S. Department of Health and Human Services, courtesy … Read more

Sonoma Biotherapeutics Welcomes Top Talent: Dr. Joseph R. Arron and Dr. Mark D. Eisner Join as CSO and CMO

October 2, 2023 by Allen Williams

Exciting developments are brewing at Sonoma Biotherapeutics, the clinical-stage biotech company focused on engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Today, … Read more

Danaher Corporation Successfully Unlocks the Future: Veralto Corporation Separation Achieved!

October 2, 2023 by Allen Williams

Today, Danaher Corporation (NYSE: DHR) proudly announces the successful completion of a significant corporate maneuver – the separation of its Environmental & Applied Solutions segment. … Read more

FDA Breaks Ground with Historic Approval: DNA Test for Dozens of Cancer Types’ Predisposition Receives First-Ever Marketing Authorization

October 2, 2023 by Allen Williams

In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, a … Read more

Amicus Triumphs: FDA Gives Green Light to Groundbreaking Treatment for Rare Muscle Disorder

October 2, 2023 by Allen Williams

Amicus Therapeutics made a groundbreaking announcement on Thursday, revealing the FDA’s approval of its transformative two-component therapy, Pombiliti + Opfolda 65-mg capsules. This approval marks … Read more

GSK Soars with Optimistic Projections: Long-Acting Antiretroviral Fuels Excitement in HIV Business Forecast

October 2, 2023 by Allen Williams

GlaxoSmithKline (GSK) is making bold predictions for its HIV business, driven by the remarkable success of its long-acting antiretroviral therapy Cabenuva. The company is now … Read more

Fabre-Kramer’s Decades-Long Quest Ends in Triumph: FDA Approval for MDD Drug Achieved!

October 2, 2023 by Allen Williams

In a significant development, the FDA has granted approval to Fabre-Kramer Pharmaceuticals for their extended-release gepirone hydrochloride tablets, set to be marketed as Exxua. This … Read more

Bionomics’ PTSD Breakthrough Sends Stock Soaring with a Remarkable 415% Leap after Successful Phase IIb Study

October 2, 2023 by Allen Williams

Exciting news emerged from Bionomics as it unveiled the results of the Phase IIb ATTUNE trial, showcasing the promising potential of its investigational ion channel … Read more

Madrigal Sets Sights High with $500M Public Offering in the Booming NASH Market Race

October 2, 2023 by Allen Williams

Madrigal Pharmaceuticals has set its sights on a substantial windfall of approximately $500 million from a public offering, with these funds earmarked to propel its … Read more

Navigating a Challenging Journey: BrainStorm’s ALS Treatment Faces Obstacles, but a Beacon of Hope Shines for Future Patients

October 2, 2023 by Allen Williams

In the world of medical breakthroughs, this week’s spotlight fell squarely on amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease. A pivotal … Read more

FDA Embraces Basilea’s Breakthrough: Ceftobiprole Antibiotic Takes Major Step Forward in New Drug Application

October 2, 2023 by Allen Williams

In the dynamic world of biopharmaceuticals, Basilea Pharmaceutica Ltd emerges as a beacon of hope, dedicated to serving patients battling severe bacterial or fungal infections. … Read more

WuXi Biologics Cheers Amicus Therapeutics as FDA Greenlights Groundbreaking Pompe Disease Treatment

October 2, 2023 by Allen Williams

In a groundbreaking achievement, WuXi Biologics, a powerhouse in the world of Contract Research, Development, and Manufacturing Organizations (CRDMOs), extends its heartfelt congratulations to its … Read more

FDA’s Next Move: Amgen, Alnylam, and BMS Await Game-Changing Decisions

October 2, 2023 by Allen Williams

In the fast-paced world of FDA decisions, the next two weeks promise to be a rollercoaster of anticipation. Brace yourselves for the verdicts on cutting-edge … Read more

Revolutionary Breakthroughs in Alzheimer’s Spark New Hope for Parkinson’s Research

October 2, 2023 by Allen Williams

In the realm of neurodegenerative diseases, the past year has witnessed a seismic shift. The FDA’s green light for Eisai and Biogen’s groundbreaking Leqembi in … Read more

BioCity Joins Forces with AstraZeneca to Pioneer Breakthrough Hepatocellular Carcinoma Treatment in China with BC3402 Monoclonal Antibody

September 28, 2023 by Allen Williams

“BioCity and AstraZeneca Join Forces for Groundbreaking Liver Cancer Study in China”BioCity Biopharma and AstraZeneca have inked a groundbreaking agreement to embark on a Phase … Read more

Spexis Welcomes Dr. Gonçalo Bernardes as Interim Head of Chemical Biology

September 28, 2023 by Allen Williams

Spexis AG, a pioneering biopharmaceutical firm specializing in rare diseases and oncology, has appointed Dr. Gonçalo Bernardes, a distinguished figure in the fields of chemistry … Read more

Exciting News: FDAQRC Announces a Wave of Well-Deserved Promotions!

September 28, 2023 by Allen Williams

FDA Quality and Regulatory Consultants (FDAQRC) is thrilled to announce the well-deserved promotions of six outstanding team members during the third quarter of 2023. These … Read more

From Capitol Hill to the Executive Suite: Ahmed Mousa’s Remarkable Journey

September 28, 2023 by Allen Williams

Ahmed Mousa’s career path is far from typical. He’s stepping into the role of CEO at Vicore after seven years with Pieris Pharmaceuticals, where he … Read more

Unlocking Success: The Compelling Case for Board Certification Among Medical Science Liaisons

September 28, 2023 by Allen Williams

The global pharmaceutical market is poised for remarkable growth, with a projected annual rate of 5.8% from 2023 to 2028, set to reach a staggering … Read more

Roche’s Bold Move: $60M Partnership with Ionis to Supercharge Efforts in Alzheimer’s and Huntington’s Diseases

September 28, 2023 by Allen Williams

In a groundbreaking move, Roche is taking a giant leap forward by allocating an upfront payment of $60 million to its long-term collaborator, Ionis Pharmaceuticals, … Read more

Game-Changer Alert: FDA Greenlights Viatris and Ocuphire’s Innovative Eye Drops to Swiftly Restore Pupils!

September 28, 2023 by Allen Williams

In an exciting development, the FDA has granted approval for the groundbreaking phentolamine ophthalmic solution jointly created by Ocuphire and Viatris. This innovative eye drop, … Read more

Unexpected Tragedy Unfolds: Gene-Editing Therapy’s Viral Delivery Raises Questions with Fatal Patient Outcome, Reveals NEJM Study

September 28, 2023 by Allen Williams

In a heart-wrenching turn of events, a recent paper in The New England Journal of Medicine unravels the possible cause behind the untimely demise of … Read more

Game-Changer Alert: Karuna’s KarXT for Schizophrenia Takes Center Stage as NDA Submission Ignites Excitement!

September 28, 2023 by Allen Williams

In a monumental move, Karuna Therapeutics sent shockwaves through the medical world as they unveiled their New Drug Application (NDA) for KarXT, a potential game-changer … Read more

Revolutionary Breakthrough: J&J’s Rybrevant and Lazertinib Combo Triumphs in Phase III for Non-Small Cell Lung Cancer Treatment!

September 28, 2023 by Allen Williams

“Medical Marvel: Janssen, a subsidiary of healthcare giant Johnson & Johnson, sent shockwaves through the world of cancer treatment last Thursday with the electrifying announcement … Read more

Takeda’s Bold Bet: Investing Nearly $600 Million in AcuraStem’s Groundbreaking ALS Program

September 27, 2023 by Allen Williams

In a groundbreaking move, Takeda, the Japanese pharmaceutical giant, has forged a visionary partnership with California-based biotech AcuraStem to tackle amyotrophic lateral sclerosis (ALS) and … Read more

Lutathera, the Breakthrough: Novartis’ Treatment Triumphs in Phase III as Pioneering Therapy for Rare Neuroendocrine Cancer

September 27, 2023 by Allen Williams

In a groundbreaking announcement on Monday, Novartis revealed the remarkable success of its radioligand therapy, Lutathera (lutetium Lu 177 dotatate), in a pivotal Phase III … Read more

Immunovant’s Stock Skyrockets as Positive Phase I Results Shine Light on Autoimmune Antibody Breakthrough

September 27, 2023 by Allen Williams

In a morning that set the stock market abuzz, Immunovant’s groundbreaking autoimmune antibody, IMVT-1402, revealed spectacular Phase I results, propelling the company’s stock prices over … Read more

Ionis Achieves Remarkable Phase III Victory in Rare Genetic Disease and Sets Sights on NDA Submission

September 27, 2023 by Allen Williams

In a momentous achievement, Ionis Pharmaceuticals has unveiled compelling topline data from the Phase III Balance study, demonstrating the remarkable efficacy of olezarsen, their antisense … Read more

Major Pharma Move: Alfasigma Acquires Troubled Intercept Pharmaceuticals in a Whopping $800 Million Cash Deal

September 27, 2023 by Allen Williams

In a blockbuster move, Italian pharmaceutical giant Alfasigma S.p.A is set to acquire Intercept Pharmaceuticals, a renowned biotech specializing in rare and severe liver diseases, … Read more

Revolutionary Advancement: VasQ™ External Support Gains FDA Clearance to Transform Arteriovenous Fistula Creation

September 27, 2023 by Allen Williams

Laminate Medical Technologies is making waves in the world of medical innovation with its VasQ External Vascular Support. This groundbreaking device has just received the … Read more

Breakthrough Moment: Smart Immune Administers Game-Changing SMART101 ProTcell Therapy to Leukemia Patients in Landmark ReSET-02 Phase I/II Trial

September 27, 2023 by Allen Williams

In a groundbreaking moment for medical science, Smart Immune, the clinical-stage biotechnology trailblazer, has marked a significant milestone. The first courageous patients have received doses … Read more

PureTech’s Bold Move: Welcoming Robert Lyne as Chief Portfolio Officer

September 27, 2023 by Allen Williams

In a momentous stride towards transforming the landscape of biotherapeutics, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) proudly introduces a new addition to its leadership … Read more

XNK Therapeutics Shines Bright at NK2023 Conference in Oslo with Dual Poster Presentations

September 27, 2023 by Allen Williams

XNK Therapeutics AB has set the scientific stage ablaze with groundbreaking revelations unveiled at the 20th Meeting of the Society for Natural Immunity (NK2023) in … Read more

Revolutionary Milestone: ONWARD® Unveils Groundbreaking Implant, ARC-IM™ BCI Stimulator, Paving the Way for Spinal Cord Injury Recovery of Arm, Hand, and Finger Functions

September 27, 2023 by Allen Williams

ONWARD Medical N.V., the trailblazing medical technology company renowned for its groundbreaking spinal cord stimulation therapies, is rewriting the future of mobility, function, and independence … Read more

AVITA Medical Clinches Top Honors: Best Product Award at the American Association for the Surgery of Trauma

September 26, 2023 by Allen Williams

In the world of regenerative medicine, AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is making waves. Their groundbreaking RECELL® System has just clinched the “Best … Read more

Precipio’s Path to Profitability: Achieving Cash Flow Breakeven with Streamlined Operations

September 26, 2023 by Allen Williams

In the world of specialty cancer diagnostics, Precipio, Inc. (NASDAQ: PRPO) is making waves. They’ve just announced a remarkable achievement—thanks to increased pathology revenue and … Read more

OMass Therapeutics Strengthens Scientific Advisory Board with Dr. Mark Namchuk, PhD

September 26, 2023 by Allen Williams

Prepare for a significant stride in the world of biotechnology as OMass Therapeutics, known for its pioneering work in identifying medicines against highly validated target … Read more

Profuse Technology Breakthrough: Transforming the Future of 3D Cultivated Meat Growth

September 26, 2023 by Allen Williams

In the ever-evolving world of muscle tissue growth, Profuse Technology emerges as a trailblazing leader. They’re not just pioneers; they’re visionaries on a mission to … Read more

Beactica Therapeutics Embarks on Exciting Partnership with the National Center for Advancing Translational Sciences

September 26, 2023 by Allen Williams

In a groundbreaking move, Beactica Therapeutics AB, the visionary Swedish precision oncology company, has forged an alliance with the National Center for Advancing Translational Sciences … Read more

WuXi Vaccines Breaks New Ground: Unveils Its Inaugural Vaccines CDMO Hub in China

September 26, 2023 by Allen Williams

Prepare to witness a seismic shift in vaccine development and manufacturing! WuXi Vaccines, a pioneering contract development and manufacturing organization (CDMO), has unveiled its inaugural … Read more

TransCode Therapeutics: Breaking Boundaries with $8 Million Public Offering

September 26, 2023 by Allen Williams

In the realm of groundbreaking cancer therapies, TransCode Therapeutics, Inc. (Nasdaq: RNAZ), is stepping into the limelight. This RNA oncology champion is on a mission … Read more

Unlocking a New Era in Research & Development: IQVIA Welcomes Richard Staub III as President of Research & Development Solutions

September 26, 2023 by Allen Williams

In a strategic move that promises to redefine the landscape of advanced analytics, technology solutions, and clinical research services for the life sciences industry, IQVIA™ … Read more

Immunovant Unveils the Future of Medicine: Join Us Live on September 26, 2023, for a Game-Changing Peek into the Initial Results of IMVT-1402 Phase 1 Trial!

September 26, 2023 by Allen Williams

Prepare to Witness a Medical Revolution! Immunovant, Inc. (Nasdaq: IMVT), the trailblazing immunology company committed to restoring normalcy in the lives of those battling autoimmune … Read more

Ascletis Achieves Milestone in Groundbreaking Glioblastoma Trial – 120 Patients Enrolled for Phase III Study of ASC40 FASN Inhibitor Combined with Bevacizumab

September 26, 2023 by Allen Williams

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) marks a remarkable milestone today as they proudly announce the culmination of patient enrollment in their Phase III registration … Read more

GeneDx Welcomes New Talent with Exciting Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 25, 2023 by Allen Williams

STAMFORD, Conn., Sept. 22, 2023 (GLOBE NEWSWIRE) — GeneDx, renowned for its dedication to enhancing health outcomes through genomic and clinical insights, is making a … Read more

Acadia Pharmaceuticals Commits to Talent with Exciting Inducement Grants – September 22, 2023

September 25, 2023 by Allen Williams

SAN DIEGO–(BUSINESS WIRE)– It’s a moment of growth and opportunity at Acadia Pharmaceuticals Inc. (Nasdaq: ACAD). On September 8, 2023, the Compensation Committee of Acadia’s … Read more

BIOQUAL Shares the Wealth with Exciting Dividend Declaration on September 22, 2023

September 25, 2023 by Allen Williams

ROCKVILLE, Md.–(BUSINESS WIRE)– Hold onto your hats, because BIOQUAL’s Board of Directors has just made an exciting announcement! They’ve declared a dividend of $0.50 per … Read more

NYSE Flags Invitae for Falling Short of Minimum Share Price Requirement

September 25, 2023 by Allen Williams

SAN FRANCISCO, September 22, 2023 — Invitae (NYSE: NVTA), a trailblazing leader in the field of medical genetics, finds itself in the spotlight as it … Read more

Roche Secures Legal Win Over Takeda in Hemophilia Patent Dispute

September 25, 2023 by Allen Williams

In a significant legal showdown, a U.S. Court of Appeals has upheld a pivotal ruling in favor of Roche’s Genentech, reinforcing that their groundbreaking hemophilia … Read more

Intarcia’s Ambitious Diabetes Breakthrough Faces Unanimous Adcomm Rejection

September 25, 2023 by Allen Williams

In a pivotal moment for diabetes treatment, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee delivered a unanimous vote against Intarcia Therapeutics’ groundbreaking investigational drug-device … Read more

AstraZeneca and Daiichi’s Breakthrough Phase III Results: A Bold Challenge to Gilead in the Battle Against Breast Cancer

September 25, 2023 by Allen Williams

The dynamic partnership that brought Enhertu to the forefront of cancer treatment is poised for yet another groundbreaking moment. AstraZeneca and Daiichi Sankyo have just … Read more

AstraZeneca and Daiichi’s Breakthrough Phase III Results: A Bold Challenge to Gilead in the Battle Against Breast Cancer

September 25, 2023 by Allen Williams

AstraZeneca and Daiichi Sankyo: Unveiling a Potential Breast Cancer Game-Changer The dynamic partnership that brought Enhertu to the forefront of cancer treatment is poised for … Read more

Navigating the FDA Regulatory Maze: Challenges Faced by These Resilient Companies

September 25, 2023 by Allen Williams

This week, the FDA served up a harsh reminder to pharmaceutical companies about the challenging path to drug approvals. ARS Pharmaceuticals, despite gaining support from … Read more

Coherus BioSciences Unveils Exciting Employment Incentives with Grants – A Game-Changer on September 23, 2023

September 25, 2023 by Allen Williams

In a bold move, Coherus BioSciences, Inc. (Nasdaq: CHRS), headquartered in the heart of REDWOOD CITY, California, has set the stage for an exciting future. … Read more

Revolutionizing Cancer Care: MediLink Therapeutics Pioneers Breakthrough ADC Research for Game-Changing Cancer Treatments

September 25, 2023 by Allen Williams

Unlocking Hope: YL201 Phase I/II Oncology Summit Sparks Excitement in Guangzhou GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ — In a momentous gathering on September 23, … Read more

Exactech Revolutionizes Ankle Solutions: Introducing Advanced Activit-E™ Polyethylene to Vantage® Portfolio

September 22, 2023 by Allen Williams

Exactech Revolutionizes Ankle Implants with Activit-E™ Polyethylene: Enhancing the Vantage® Total Ankle System” Exactech, a trailblazer in innovative joint replacement solutions, has received FDA 510(k) … Read more

MicroVention’s Bold Move into Cutting-Edge Transradial Access Therapy: FDA Greenlights SOFIA™ EX 5F 115cm Intracranial Support Catheter

September 22, 2023 by Allen Williams

MicroVention Makes Waves in Neurovascular Advancements: FDA Gives Green Light to SOFIA™ EX 5F Catheter for Transradial Access ALISO VIEJO, Calif.–(BUSINESS WIRE)– In a groundbreaking … Read more

Unlocking Hope: Transcend Therapeutics and Yale Join Forces with U.S. Department of Defense to Investigate Methylone for PTSD

September 22, 2023 by Allen Williams

NEW YORK, Sept. 21, 2023 /PRNewswire/ — Transcend Therapeutics, the visionary biotech on a mission to revolutionize neuropsychiatric treatments, proudly announces a transformative partnership with … Read more

Aditum Bio Breaks New Ground with Celexor Bio: Pioneering Cell Depletion for Tackling Autoimmune and Inflammatory Disorders

September 22, 2023 by Allen Williams

OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Aditum Bio, the brainchild of former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for … Read more

Closing the Skills Gap: Innovative Training Models Revolutionize Biopharma Manufacturing Workforce

September 22, 2023 by Allen Williams

In the dynamic world of biopharmaceutical manufacturing, the hunger for skilled professionals is surging ahead, but the talent pool is struggling to keep pace. This … Read more

Genentech’s Billion-Dollar Bet: Orionis Deal Sets the Stage for Breakthrough Glue Degraders

September 22, 2023 by Allen Williams

In a stunning display of commitment to innovation, Roche’s Genentech has unleashed a flurry of R&D deals, including a high-stakes partnership with Orionis Biosciences worth … Read more

Civica Rx’s Innovative Approach Boosts Drug Supply Reliability and Slashes Expenses, According to Study

September 22, 2023 by Allen Williams

A groundbreaking analysis published in NEJM Catalyst reveals how Civica Rx, a not-for-profit drug manufacturer, has transformed the landscape of drug supply security while dramatically … Read more

Alvotech Seizes a Triumphant Third Shot: FDA Greenlights BLA for Game-Changing Humira Biosimilar

September 22, 2023 by Allen Williams

In a thrilling twist, the FDA has accepted Alvotech’s latest Biologics License Application (BLA) for AVT02, a high-concentration and interchangeable biosimilar aiming to dethrone AbbVie’s … Read more

Resilient Mesoblast: FDA Meeting Sparks New Hope for Previously Rejected Cell Therapy

September 22, 2023 by Allen Williams

In a remarkable twist of fate, Mesoblast has emerged from the shadows with renewed determination, claiming a newfound understanding of the FDA’s demands following a … Read more

Travere’s Exciting Kidney Disease Breakthrough Falls Just Short in Phase III, Sends Stock on a Rollercoaster Ride

September 22, 2023 by Allen Williams

Travere Therapeutics made waves on Thursday with a dramatic Phase III showdown for its kidney disease wonder drug, sparsentan, affectionately known as Filspari. The stage … Read more

Rezo Therapeutics Welcomes Dr. Nadir Mahmood as the New Captain at the Helm

September 21, 2023 by Allen Williams

Rezo Therapeutics, a trailblazing biotech firm revolutionizing disease mapping for targeted therapeutics, makes waves with the appointment of Dr. Nadir Mahmood as the dynamic Chief … Read more

Major Milestone: Hepagene Therapeutics Gets Green Light from FDA for HPG7233 THR Beta Agonist’s Investigational New Drug Application (IND)

September 25, 2023September 21, 2023 by Allen Williams

HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ — In a groundbreaking development, Hepagene Therapeutics, Inc., a visionary clinical-stage biopharmaceutical powerhouse, proudly announces the … Read more

Pioneering Progress: OnKure Therapeutics Welcomes Dr. Ann Howell as Vice President of Regulatory Affairs

September 21, 2023 by Allen Williams

BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) — In an exciting move, OnKure, Inc., a dynamic clinical-stage biopharmaceutical company shaping the future of precision oncology, … Read more

Unlocking the Future: A Glimpse at 5 Game-Changing Life Sciences IPOs of 2023 and Beyond

September 21, 2023 by Allen Williams

Compared to the IPO bonanzas of recent years, 2023 has felt like a chilly desert in the biotech world. In 2022, a whopping 47 IPOs … Read more

Facing a Tough Crossroads: Fresh Tracks and Histogen Prepare to Close Doors Amidst Limited Options

September 21, 2023 by Allen Williams

In a somber turn of events, Colorado-based pharma Fresh Tracks and California biotech Histogen have both declared their intentions to dissolve and liquidate their businesses. … Read more

Lilly Takes Legal Stand Against Unapproved Mounjaro Imitations: Pharmacies, Spas, and Wellness Centers in the Crosshairs

September 21, 2023 by Allen Williams

Eli Lilly isn’t holding back as it takes the legal battlefield by storm, aiming to protect its flagship drug, Mounjaro. The pharmaceutical giant is unleashing … Read more

ReCode Secures a Whopping $260 Million Boost in Series B Funding to Power Its Trailblazing Initiatives

September 25, 2023September 21, 2023 by Allen Williams

In a financial triumph, ReCode Therapeutics has just concluded a dazzling extension round for its Series B funding, raking in an additional $50 million. This … Read more

Surprising Twist: Despite Adcomm Backing, FDA Declines ARS’ Epinephrine Nasal Spray

September 21, 2023 by Allen Williams

In a surprising twist, the FDA dealt a setback to ARS Pharmaceuticals on Tuesday by rejecting its application for the groundbreaking epinephrine nasal spray known … Read more

Genentech and PeptiDream Join Forces in Groundbreaking $1 Billion Radiopharma Partnership

September 21, 2023 by Allen Williams

In a thrilling development, Japanese biopharma powerhouse PeptiDream has announced yet another groundbreaking partnership, this time with Genentech, a subsidiary of Roche, with a jaw-dropping … Read more

Taysha’s Bold Move: Halting Gene Therapy Candidate as FDA Demands Game-Changing Study Updates

September 21, 2023 by Allen Williams

In a surprising turn of events, Taysha Gene Therapies has decided to part ways with its leading experimental AAV-based gene therapy candidate, TSHA-120, following the … Read more

Welcome Back: Kathleen P. Bloch Returns as Full-Time Chief Financial Officer at CytoSorbents

September 20, 2023 by Allen Williams

Kathleen P. Bloch Returns to the Helm as Full-Time CFO at CytoSorbents – A Strategic Move for an Exciting Future! PRINCETON, N.J., Sept. 19, 2023 … Read more

Nostics Welcomes Medtech Visionary Jeroen Nieuwenhuis as New CEO

September 20, 2023 by Allen Williams

Exciting News from Amsterdam: Nostics Welcomes Seasoned Medtech Innovator, Jeroen Nieuwenhuis, as CEO Amsterdam, September 19, 2023 – Nostics, a groundbreaking medical diagnostics startup, is … Read more

Revolutionizing Spatial Biology: Akoya Biosciences Unveils Game-Changing 2.0 Platforms

September 20, 2023 by Allen Williams

Akoya Biosciences Unleashes Breakthrough 2.0 Platforms, Paving the Way for Unprecedented Advancements in Spatial Biology MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences … Read more

Revolution Medicines Marks a Milestone: First Patient Receives Groundbreaking Treatment RMC-9805, Targeting Mutant KRASG12D(ON)

September 25, 2023September 20, 2023 by Allen Williams

Revolution Medicines Launches Clinical Journey for Groundbreaking Cancer Treatment: First Patient Dosed in Trial of RMC-9805, a Game-Changing KRASG12D(ON) Inhibitor REDWOOD CITY, Calif., Sept. 19, … Read more

Hepion Pharmaceuticals Unveils Exciting New Insights into Rencofilstat’s Impact on Liver Cancer

September 20, 2023 by Allen Williams

Unlocking a Powerful Weapon Against Liver Cancer: Hepion Pharmaceuticals’ Breakthrough Discovery EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — In a groundbreaking revelation, Hepion Pharmaceuticals, … Read more

FDA Greenlights Orchard’s Rare Disease Gene Therapy, Following EU’s Stamp of Approval

September 20, 2023 by Allen Williams

Hope on the Horizon: Orchard Therapeutics’ Breakthrough Gene Therapy for Rare Disease Gains FDA Priority Review In a game-changing move, the FDA has given the … Read more

Sanofi Makes a Strategic Move: Offloads 11 CNS Assets, Including Frisium and Gardenal, to Pharmanovia

September 20, 2023 by Allen Williams

Sanofi’s Strategic Shake-Up: 11 CNS Drugs, Including Frisium and Gardenal, Find a New Home with Pharmanovia In a bold move on Monday, Sanofi parted ways … Read more

Astellas Soars with Izervay: Exciting Phase III Results in Geographic Atrophy, Paving the Way for Label Expansion

September 20, 2023 by Allen Williams

Astellas Pharma’s Izervay, an eye injection treatment, is on a rapid ascent just six weeks after gaining FDA approval. Now, the company has set its … Read more

BeiGene Reclaims Tislelizumab as Novartis Surrenders Cancer Asset

September 20, 2023 by Allen Williams

Novartis Makes a Strategic Pivot: Returns Cancer Drug Tislelizumab to BeiGene as Europe Approves Tevimbra In a noteworthy twist of pharmaceutical fate, Novartis has handed … Read more

Amgen-Horizon Merger Sparks Turbulence in FTC’s Antitrust Battle!

September 20, 2023 by Allen Williams

In a surprising turn of events on September 1, the U.S. Federal Trade Commission gave the green light to Amgen’s colossal $27.8 billion takeover of … Read more

B. Braun Achieves FDA Clearance for Next-Gen AQUAbase® Reverse Osmosis System

September 19, 2023 by Allen Williams

B. Braun Introduces Revolutionary Dialysis Solution: AQUAbase nX – Purity without Chemicals BETHLEHEM, Pa., Sept. 18, 2023 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), … Read more

Breaking Ground in Drug Discovery: Unravel Unveils rareSHIFT™ – A Revolutionary End-to-End Solution

September 19, 2023 by Allen Williams

BOSTON, Sept. 18, 2023 /PRNewswire/ — Unravel Biosciences, Inc., (“Unravel”), a pioneer in therapeutics powered by cutting-edge machine learning, is set to revolutionize the landscape … Read more

Breaking Boundaries: FDA Clears Precision BioLogic’s Factor VIII Deficient Plasma with VWF for Sale in the U.S

September 19, 2023 by Allen Williams

Revolutionizing Hemophilia Care: Precision BioLogic’s Breakthrough CRYOcheck™ Factor VIII Deficient Plasma Now FDA-Cleared for U.S. Market Halifax, NS – September 18, 2023 – Precision BioLogic … Read more

Breaking Ground in Mental Health: Motif Neurotech Unveils Remarkable Brain Stimulation Using Tiny Implant for Treatment-Resistant Depression in First-Ever Human Trial

September 19, 2023 by Allen Williams

Revolutionizing Mental Health Treatment: Tiny Brain Stimulator Offers Hope for Treatment-Resistant Depression HOUSTON–(BUSINESS WIRE)–In a groundbreaking collaboration between Motif Neurotech, Rice University, Baylor College of … Read more

Revolutionizing Drug Delivery: Rani Therapeutics Launches Phase 1 Trial of RT-111 (RaniPill® Loaded with Ustekinumab Biosimilar, CT-P43)

September 19, 2023 by Allen Williams

SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a trailblazing biotherapeutics company, is embarking … Read more

Navigating Ambiguity: Karyopharm’s Selinexor Seeks to Build on Early Triumphs in an Evolving Landscape

September 19, 2023 by Allen Williams

Karyopharm Therapeutics: Navigating a Complex Path to Expansion for Selinexor Since Karyopharm Therapeutics secured accelerated FDA approval for selinexor in combination with dexamethasone for relapsed … Read more

High-Stakes Showdown: DOJ and Chamber of Commerce Lock Horns in Court Battle Over IRA’s Drug Price Negotiations

September 19, 2023 by Allen Williams

High-Stakes Legal Clash: DOJ and Chamber of Commerce Face Off in Ohio Court Over IRA’s Drug Price Negotiations In a riveting courtroom battle, lawyers for … Read more

FDA Greenlights GSK’s Revolutionary Momelotinib: New Hope for Myelofibrosis Patients Battling Anemia

September 19, 2023 by Allen Williams

FDA Grants Green Light to GSK’s Ojjaara: A Game-Changer for Myelofibrosis Patients Battling Anemia! In a monumental decision on Friday, the FDA gave the nod … Read more

Game-Changer Alert: Anthos Halts Mid-Stage Atrial Fibrillation Trial Amidst ‘Unprecedented’ Success!

September 19, 2023 by Allen Williams

In a sensational twist, Anthos Therapeutics has decided to halt its Phase II AZALEA-TIMI 71 study prematurely. The reason is their experimental monoclonal antibody, abelacimab, … Read more

Samsung Biologics and BMS Join Forces in $242M Pact to Power Up Cancer-Fighting Antibodies!

September 19, 2023 by Allen Williams

In a whirlwind year of groundbreaking partnerships, Samsung Biologics is making waves in the biotech world. The South Korean powerhouse has just expanded its collaboration … Read more

Rising Challenge, Rising Innovation: Tackling Substance Use Disorders with Creative Solutions

September 18, 2023 by Allen Williams

July marked a pivotal moment in the quest to combat the devastating impact of substance use disorders (SUD). The FDA gave the green light to … Read more

Landmark Resolution: AstraZeneca’s Alexion Strikes $125 Million Accord in Soliris Sales Lawsuit

September 18, 2023 by Allen Williams

AstraZeneca’s Alexion Resolves Long-Standing Legal Saga: $125M Settlement in Soliris Sales Battle! In a legal faceoff that has spanned several years, AstraZeneca’s rare diseases arm, … Read more

Biotech Breakthrough: RayzeBio’s $311M and Neumora’s $250M IPOs Lead the Charge in 2023!

September 18, 2023 by Allen Williams

Biotech IPOs Roar Back to Life: RayzeBio and Neumora’s Combined $560M Triumph Signals a Resurgence! In a thrilling twist for the world of initial public … Read more

Promising Breakthrough: Blarcamesine by Anavex Shown to Stall Cognitive Decline in Alzheimer’s Patients

September 18, 2023 by Allen Williams

Game-Changer Alert: Blarcamesine by Anavex Shows Remarkable Promise in Slowing Alzheimer’s Cognitive Decline! In a remarkable turn of events, Anavex Life Sciences has revealed that … Read more

Novartis Unleashes Sandoz: Shareholders Embrace Bold Spin-Off Amidst Soaring Product Ambitions!

September 18, 2023 by Allen Williams

Sandoz Gears Up for Independence: Novartis Shareholders Give the Nod to Epic Spin-Off! After a year-long journey toward independence, Sandoz, Novartis’ generics and biosimilars division, … Read more

Biotech Finance: A Ray of Hope? The IPO Wave May Be Shifting Back in Favor!

September 18, 2023 by Allen Williams

Biotech Finance: Riding the Wave of Resurgence – Big IPOs, Bold Moves, and Regulatory Drama! The biotech sector is buzzing with excitement as a shift … Read more

Revolutionary Drug Breakthrough Halts Aging Process in Organ Transplants

September 18, 2023 by Allen Williams

ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ — In a groundbreaking revelation, a new class of drugs called Senolytics is emerging as the savior in the … Read more

Zylox-Tonbridge Makes a Powerful Entry into the Prestigious FTSE Global Equity Index Series

September 18, 2023 by Allen Williams

HANGZHOU, China – Sept. 18, 2023 – In a thrilling turn of events, Zylox-Tonbridge (2190.HK, fondly known as “the Company”) has just secured a spot … Read more

Samsung Biologics Amplifies Partnership with Bristol Myers Squibb, Scaling Up Production of Cutting-Edge Antibody Cancer Treatment

September 18, 2023 by Allen Williams

INCHEON, South Korea – Sept. 17, 2023 – Today, in a groundbreaking move, Samsung Biologics (KRX: 207940.KS) has unveiled a strategic alliance that promises to … Read more

Inaugural BioTechX USA: Fusing the Forces of Science and Technology

September 18, 2023 by Allen Williams

In an era where the life sciences industry undergoes a rapid digital evolution, the debut of BioTechX USA in sunny Santa Clara this September was … Read more

Virginia Oncology Associates Embrace Cutting-Edge Infusion System by Fresenius Kabi: A Pioneering Step in Patient Care

September 15, 2023 by Allen Williams

Fresenius Kabi Partners with Virginia Oncology Associates to Revolutionize Patient Care: Introducing the Ivenix Infusion System for Enhanced Medication Delivery LAKE ZURICH, Ill.–(BUSINESS WIRE)–Fresenius Kabi … Read more

Unlocking the Seal: Pasithea Therapeutics Corp. Unveils Definitive Outcomes of Tender Offer

September 15, 2023 by Allen Williams

Unlocking Opportunities: Pasithea Therapeutics Corp. Empowers Stockholders with Successful Tender Offer PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. … Read more

The Symphony of Genes: How Genome Variants Dance with Each Other and the Environment, Shaping Cardiovascular Risk

September 15, 2023 by Allen Williams

Unveiling the Genetic Tango: How Variants in Our DNA Choreograph Cardiovascular Health REYKJAVIK, Iceland, Sept. 14, 2023 /PRNewswire/ — Step into the captivating world of … Read more

OKYO Pharma’s Surprise Move: Cancels Public Offering Plans

September 15, 2023 by Allen Williams

OKYO Pharma’s Bold Move: Pulls the Plug on Public Offering Amid Shifting Market Tides LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) — OKYO … Read more

The Balancing Act in Cancer Immunotherapy: Why Less Might Be More

September 15, 2023 by Allen Williams

Cancer’s Mismatched Battle: Unmasking the Surprising Key to Effective Immunotherapy In the realm of cancer immunotherapy, the assumption has long been that more genetic mutations … Read more

Pioneering Biotech Ventures into Uncharted Territory: Inhaled Gene Therapies for Rare Respiratory Disorders

September 15, 2023 by Allen Williams

Breaking Ground in Respiratory Care: Oxford’s AlveoGene Unveils Vision for Inhaled Gene Therapies In a groundbreaking debut, Oxford-based biotech AlveoGene has burst onto the scene, … Read more

AbbVie’s Bold Move: Opts Out of Licensing Harpoon’s Innovative TriTAC Program for Multiple Myeloma

September 15, 2023 by Allen Williams

AbbVie Opts Out of Exclusive License for Harpoon’s Innovative Multiple Myeloma Therapy In a surprising twist, AbbVie has decided not to exercise its exclusive licensing … Read more

Moderna Takes the Scalpel to Four Clinical Ventures, Rescuing Two Castaways AstraZeneca Left Behind

September 15, 2023 by Allen Williams

Moderna Drops Four Clinical Initiatives, Rescuing Two Left Adrift by AstraZeneca In a strategic shake-up, Moderna made waves on Wednesday by trimming its clinical development … Read more

Groundbreaking AI Firm Generate Secures a Whopping $273 Million in Series C Funding, Welcoming Amgen and NVIDIA as Key New Backers

September 15, 2023 by Allen Williams

In a major funding coup, AI-centric startup Generate:Biomedicines has scored an impressive $273 million windfall in its Series C financing round, thanks to the backing … Read more

BMS Axes Two Promising Mid-Stage and Shelves Four Exciting Early-Stage Clinical Projects

September 15, 2023 by Allen Williams

Bristol Myers Squibb, in a bold move unveiled during an R&D Day event, has pruned its development portfolio by axing two mid-stage and shelving four … Read more

Exciting News: Uvax Bio Welcomes Dr. Pedro Garbes as Global Medical Lead VP!

September 14, 2023 by Allen Williams

WILMINGTON, Del.—In a groundbreaking move, Uvax Bio LLC, the trailblazing vaccine biotechnology firm renowned for its cutting-edge 1c-SApNP® vaccine design platform, has welcomed Dr. Pedro … Read more

Breaking News: Adagio Medical Takes Bold Step Towards Revolutionizing Heart Care with Ultra-Cold Cryoablation for Ventricular Arrhythmias in the US

September 14, 2023 by Allen Williams

LAGUNA HILLS, Calif., Sept. 13, 2023 /PRNewswire/ — In a monumental stride towards revolutionizing heart care, Adagio Medical, Inc. has taken the world of cardiac … Read more

The Intriguing World of Biopharma Investments: Why Companies Purchase Stock in Each Other

September 14, 2023 by Allen Williams

On a fateful day in late June, Gilead Sciences made waves in the biopharmaceutical world with a bold financial move. They acquired a staggering 3 … Read more

Neurocrine Achieves Milestone as Congenital Adrenal Hyperplasia Candidate Triumphs in Phase III Trial

September 14, 2023 by Allen Williams

Neurocrine’s Breakthrough: Hope on the Horizon for Congenital Adrenal Hyperplasia as Phase III Trial Succeeds In a significant stride forward, Neurocrine Biosciences has unveiled the … Read more

Skyrizi Surpasses Stelara: AbbVie’s Breakthrough in Late-Stage Crohn’s Disease Trial

September 14, 2023 by Allen Williams

Skyrizi Triumphs Over Stelara: AbbVie’s Breakthrough in Crohn’s Disease Trial In a head-to-head showdown, AbbVie’s Skyrizi (risankizumab) has not only matched but potentially outpaced Johnson … Read more

Safety Concerns Force Eiger to Halt Phase III Hepatitis Study

September 14, 2023 by Allen Williams

Eiger Halts Phase III Hepatitis Study Amid Safety Concerns, Sending Stocks Tumbling Eiger BioPharmaceuticals dropped a bombshell on Tuesday, announcing the abrupt discontinuation of its … Read more

Moderna Shifts Gears: Pioneering mRNA Medicines as COVID Vaccine Production Takes a New Direction

September 14, 2023 by Allen Williams

Moderna’s Ambitious Leap Beyond COVID: Unveils Plan for 15 New Medicines in the Next 5 Years In a bold move to diversify beyond its COVID-19 … Read more

Alnylam Triumphs: Adcomm Backs Heart Disease Drug Despite FDA’s Worries

September 14, 2023 by Allen Williams

Adcomm Backs Alnylam’s Heart Disease Drug Despite FDA Concerns: A Close Vote with Patient Perspective in Focus” In a closely-watched decision, the FDA’s Cardiovascular and … Read more

Exploring Uncharted Research Avenues: The Fascinating World of Postdoc Programs in Pharmaceutical Companies

September 14, 2023 by Allen Williams

In the dynamic realm of biomedical sciences, postdoctoral positions are often regarded as the stepping stones for freshly minted PhDs, offering pathways into promising careers … Read more

Biopharma Career Fairs Stage a Remarkable Revival: Get Ready for the Excitement!

September 14, 2023 by Allen Williams

Amid the pandemic, the rise of virtual job fairs was nothing short of a game-changer, especially in the realm of higher education and the pharmaceutical … Read more

CARGO Therapeutics Welcomes Dr. Michael Ports as Chief Scientific Officer, Igniting a New Era of Innovation

September 13, 2023 by Allen Williams

CARGO Therapeutics Welcomes Dr. Michael Ports as Chief Scientific Officer, Pioneering the Future of Cell Therapy for Cancer” Dr. Michael Ports, a trailblazing leader in … Read more

Nuvectis Pharma Takes a Bold Step Forward with Commencement of NXP900 Phase 1a Clinical Trial

September 13, 2023 by Allen Williams

In the realm of medical innovation, Nuvectis Pharma, Inc. (NASDAQ: NVCT), a trailblazing clinical-stage biopharmaceutical company, embarks on a groundbreaking journey. Their focus? Revolutionizing the … Read more

Bolt Biotherapeutics Secures U.S. Patent for Game-Changing Dectin-2-Targeting Agonist Antibodies, with a Spotlight on BDC-3042

September 13, 2023 by Allen Williams

In a groundbreaking development, Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a visionary player in the field of cancer immunotherapy, has just achieved a significant milestone. The … Read more

Sensorium Therapeutics Welcomes Life Sciences Veteran Mr. David Southwell to its Board of Directors for an Exciting New Chapter

September 13, 2023 by Allen Williams

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) — Sensorium Therapeutics (Sensorium), a pioneering biotechnology company that draws inspiration from nature and human experiences to unlock groundbreaking … Read more

Menarini Asia-Pacific Scores Exclusive Deal with Astellas to Bring Innovative Smyraf® to Taiwan and Key Southeast Asian Markets

September 13, 2023 by Allen Williams

In a groundbreaking move, Menarini Asia-Pacific has joined forces with Astellas Pharma Inc., setting the stage for a dynamic partnership aimed at revolutionizing the treatment … Read more

Rome’s Remarkable Funding Coup: J&J and BMS Propel Series B Total to a Whopping $149 Million

September 13, 2023 by Allen Williams

Rome Therapeutics Hits Jackpot: J&J and BMS Join the Investment Party, Boosting Series B Total to $149 Million In a thrilling twist for Boston’s cutting-edge … Read more

Sandoz Joins Forces with Samsung Bioepis to Bring Game-Changing Biosimilar for J&J’s Stelara to Market

September 13, 2023 by Allen Williams

Sandoz Strikes Exclusive Deal with Samsung Bioepis for Game-Changing Biosimilar to J&J’s Stelara In a groundbreaking move, Sandoz, a division of Novartis, has inked a … Read more

Disappointment for Acelyrin: Promising Izokibep Falls Short in Advanced Hidradenitis Suppurativa Study

September 13, 2023 by Allen Williams

Acelyrin’s Hidradenitis Suppurativa Drug Misses Mark, but Hope Persists In a rollercoaster ride for Acelyrin, the company revealed top-line data from a Phase IIb/III trial … Read more

2seventy’s Bold Restructuring Move: CEO Out as Company Sheds 40% of Workforce

September 13, 2023 by Allen Williams

2seventy Bio’s Bold Move: CEO Steps Down as Company Slashes Workforce and Refocuses on Profitability In a dramatic shift, 2seventy Bio has initiated a comprehensive … Read more

FDA Raises Doubts About Alnylam’s Groundbreaking Drug for ATTR-CM Just Before Crucial Adcomm Meeting

September 13, 2023 by Allen Williams

Alnylam Pharmaceuticals Faces Roadblock in Expanding Patisiran’s Reach for Treating Heart Conditions Alnylam Pharmaceuticals’ ambitious bid to extend the potential uses of its groundbreaking drug, … Read more

Zynex Unveils Strategic Share Repurchase Initiative to Strengthen Market Position

September 12, 2023 by Allen Williams

Zynex Empowers Shareholders with $10 Million Stock Repurchase Plan ENGLEWOOD, Colo., Sept. 11, 2023 /PRNewswire/ — In a strategic move to fortify its market position, … Read more

Breaking Ground: Genesis MedTech Unveils China’s Inaugural NPMA-Approved Antibacterial Suture Brand

September 12, 2023 by Allen Williams

Singapore-based Genesis MedTech, a prominent player in the medical device arena, has just scored a remarkable victory with its newly approved absorbable sutures featuring cutting-edge … Read more

OrthoPediatrics Achieves FDA Milestone with Innovative Pediatric Nailing Platform for Tibia

September 12, 2023 by Allen Williams

In a groundbreaking development, OrthoPediatrics Corp. (NASDAQ: KIDS) has just received the green light from the U.S. Food and Drug Administration (FDA) for its innovative … Read more

Exciting FDA Developments: GSK and Alnylam Await a Momentous Decision

September 12, 2023 by Allen Williams

This week promises high-stakes decisions in the world of pharmaceuticals, with GSK eagerly anticipating the fate of its myelofibrosis breakthrough, momelotinib. Meanwhile, Alnylam is set … Read more

Critical Analysis: A Second Look at a Disappointing DMD Trial Signals a Turning Point for FibroGen

September 12, 2023 by Allen Williams

In a surprising turn of events, FibroGen, which initially showed promise in its Phase II trial, recently dropped a bombshell with the disappointing topline results … Read more

Breaking News: Moderna and Immatics Join Forces in a Landmark $1.8 Billion Oncology Pact, Unveiling the Future of Cancer Vaccines

September 12, 2023 by Allen Williams

In a groundbreaking move, vaccine giant Moderna and pioneering oncology biotech company Immatics have sealed a transformative research partnership worth over $1.8 billion in potential … Read more

Medical Breakthrough: Crinetics Triumphs in Phase III with a Once-Daily Pill for Rare Disease Acromegaly

September 12, 2023 by Allen Williams

In a groundbreaking announcement, Crinetics Pharmaceuticals revealed that its oral investigational wonder drug, paltusotine, has not only met but exceeded expectations in the Phase III … Read more

Novartis Makes a Strategic Pivot: Excludes Eye Disease Gene Therapy in $800M Gyroscope Deal

September 12, 2023 by Allen Williams

In a surprising turn of events, Novartis has decided to part ways with GT005, an eye disease gene therapy, despite its $800 million acquisition of … Read more

Breaking News: Gilead’s Trodelvy Emerges as Promising First-Line Therapy for NSCLC

September 12, 2023 by Allen Williams

In a groundbreaking development, early data from the Phase II EVOKE-02 study has unveiled a potential game-changer in the fight against metastatic non-small cell lung … Read more

FDA Greenlights Moderna and Pfizer-BioNTech’s Enhanced COVID-19 Vaccines for Battle Against Variants

September 12, 2023 by Allen Williams

In a timely move for the upcoming fall vaccination season, the FDA has given the green light to updated COVID-19 booster shots from Pfizer-BioNTech and … Read more

BioInvent Breaks Ground: Commences Subcutaneous Phase 1/2 Trial of BI-1206 for Solid Tumors

September 11, 2023 by Allen Williams

BioInvent Hits Milestone: Initiates Patient Treatment with Convenient Subcutaneous BI-1206 for Solid Tumors LUND, SE / ACCESSWIRE / September 08, 2023 / In a groundbreaking … Read more

Mark Your Calendar: Zealand Pharma’s Exclusive Obesity R&D Extravaganza Set to Illuminate London on December 5, 2023

September 11, 2023 by Allen Williams

Copenhagen, Denmark, September 8, 2023 – Brace yourself for a transformative event as Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a pioneering biotechnology company dedicated … Read more

Golden Collaboration: Gold Colloid, Co. and Claremont BioSolutions Join Forces to Bring Gold Nanoparticles to the World

September 11, 2023 by Allen Williams

La Mesa, CA – September 8, 2023 – Two industry titans, Gold Colloid, Co., a trailblazing point-of-care (POC) test development company, and Claremont BioSolutions LLC, … Read more

Brainomix Joins Forces with TIPAL Trial to Unlock the Potential of a Groundbreaking IPF Biomarker in Lung Disease

September 11, 2023 by Allen Williams

Brainomix Pioneers a Revolutionary Partnership with TIPAL Trial to Redefine IPF Treatment OXFORD, UK, September 8, 2023 – Brainomix is set to make medical history … Read more

Sirtex Medical and Magle Group Join Forces to Unleash the Power of EmboCept® S DSM 50 μm

September 11, 2023 by Allen Williams

Sirtex Medical and Magle Group Join Forces to Combat Liver and Lung Cancer Globally WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ — In a landmark collaboration, … Read more

Otsuka and Shape Join Forces in a Visionary Quest: $1.5 Billion Deal to Pioneer Eye AAV Gene Therapies

September 11, 2023 by Allen Williams

Otsuka and Shape Join Forces in a $1.5 Billion Vision to Revolutionize Ocular Gene Therapies In an electrifying development, Japan’s Otsuka Pharmaceuticals unveiled a transformative … Read more

Humira Faces Challenge from Biosimilars and Next-Gen Therapies, Shaping the Future of AbbVie

September 11, 2023 by Allen Williams

The Crohn’s disease market in the United States is undergoing a seismic transformation, triggered by the debut of the first Humira (adalimumab) biosimilars in July. … Read more

Seagen and Nurix Forge a Cutting-Edge Alliance to Unleash Revolutionary Cancer-Killing Antibody Conjugates

September 11, 2023 by Allen Williams

Seagen and Nurix Unite Forces in $3.4 Billion Quest to Revolutionize Cancer Treatment In a groundbreaking collaboration, Seagen and Nurix Therapeutics are set to rewrite … Read more

High-Stakes Drama Unfolds: Astellas Drops IRA Lawsuit, Illumina Welcomes New CEO, and More in This Week’s Recap!

September 11, 2023 by Allen Williams

Last Week’s Headlines: Pharma Giants Face Off Against Medicare, Illumina’s Leadership Shake-Up, and Surprising Trends in the Life Sciences Workforce Last week witnessed a dramatic … Read more

AstraZeneca and Verge Forge Cutting-Edge Partnership to Revolutionize Drug Discovery with AI

September 11, 2023 by Allen Williams

AstraZeneca’s Alexion division and Verge Genomics Embark on a $840 Million Odyssey to Unearth Rare Disease Miracles with AI In an extraordinary leap forward, AstraZeneca’s … Read more

Energizing Progress: Syros Announces Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4) on September 7, 2023

September 8, 2023 by Allen Williams

Unlocking Potential: Syros Pharmaceuticals Empowers New Talent with Rewarding Stock Grants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a pioneering biopharmaceutical company dedicated to redefining the forefront … Read more

Elevating Expertise: Pleco Therapeutics Welcomes Dr. Henno Welgemoed as Chief Medical Officer

September 8, 2023 by Allen Williams

Unlocking New Horizons: Pleco Therapeutics Appoints Dr. Henno Welgemoed as Chief Medical Officer Nijmegen, The Netherlands – 5 September 2023 – In a significant move, … Read more

Breaking Ground: Aruna Bio Unveils Promising Preclinical Findings in Pilot Study for Amyotrophic Lateral Sclerosis Treatment AB126

September 8, 2023 by Allen Williams

Hope on the Horizon: Aruna Bio’s Breakthrough Preclinical Results Offer Potential ALS Treatment BOSTON and ATHENS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) — Aruna Bio, … Read more

Seeding Diversity: How Feeder Programs Pave the Way for Inclusivity in the Pharma Industry

September 8, 2023 by Allen Williams

In a groundbreaking initiative, Eli Lilly and Purdue University have rolled out a scholarship program that welcomes its first cohort of 98 students. Their mission? … Read more

Explosive Accusations: HMO Claims BMS Engaged in Patent Fraud to Preserve Pomalyst Monopoly

September 8, 2023 by Allen Williams

Legal Fireworks: Blue Cross and Blue Shield of Louisiana Drops a Bombshell Lawsuit on Bristol Myers Squibb Over Pomalyst In a stunning legal showdown, Blue … Read more

Astellas Drops Legal Battle Over Xtandi as Drug’s Pricing Drama Takes an Unexpected Turn

September 8, 2023 by Allen Williams

In a surprising twist, Astellas Pharma has chosen to wave the white flag, voluntarily dismissing its legal challenge against the Department of Health and Human … Read more

Roche Strikes Gold: $310 Million Investment in Alnylam Pays Off Big with Phase II Hypertension Victory

September 8, 2023 by Allen Williams

Alnylam’s Hypertension Breakthrough: Roche Partnership Pays Off in Phase II Triumph In a stunning turn of events, Alnylam Pharmaceuticals is sprinting ahead with its game-changing … Read more

CymaBay’s Liver Miracle: Phase III Triumph Unlocks Hope with Stellar Results on Liver Disease Breakthrough

September 8, 2023 by Allen Williams

CymaBay Therapeutics Achieves Liver Breakthrough: Seladelpar Hits Bullseye in Phase III Trial In a groundbreaking development, CymaBay Therapeutics announced a stunning victory for its liver … Read more

Shockwaves in Medical World as J&J Abruptly Halts Phase III Trial of Potential Game-Changer Opsumit for Pulmonary Hypertension

September 8, 2023 by Allen Williams

J&J’s Thrilling Medical Frontier: Opsumit’s Surprising Phase III Halt Shakes Up Pulmonary Hypertension Realm In an unexpected twist, J&J subsidiary Janssen rocked the medical world … Read more

Revolutionizing Cell Therapy Manufacturing: Thermo Fisher Scientific Unveils Cutting-Edge Gibco™ CTS™ Detachable Dynabeads™ Platform for Lightning-Fast Progress

September 7, 2023 by Allen Williams

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the global pioneer in scientific advancement, unveils its groundbreaking Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads)*, a next-gen Dynabeads … Read more

OncoNano and Regeneron Forge Innovative Partnership: Libtayo® Joins ONM-501 Study in Exciting Clinical Trial Collaboration

September 7, 2023 by Allen Williams

In a groundbreaking move, OncoNano Medicine, Inc., based in SOUTHLAKE, Texas, has unveiled a pivotal clinical trial supply agreement with none other than Regeneron, heralding … Read more

MaxCyte Welcomes Ali Soleymannezhad as Executive Vice President, Pioneering Bioprocessing Advancements

September 7, 2023 by Allen Williams

In a strategic move aimed at pushing the boundaries of cell-based therapeutics, MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a trailblazing player in cell engineering, has … Read more

Exciting Times in Cardiology: Phase III Heart Failure Trial Casts Doubt on BioCardia’s Cell Therapy’s Primary Goal

September 7, 2023 by Allen Williams

California-based BioCardia dropped a bombshell on Tuesday, revealing that its cutting-edge cell therapy, CardiAMP, aimed at combating heart failure, may not achieve its primary goal, … Read more

Medicare’s Negotiation Power: A Potential Game-Changer with Surprising Financial Prospects

September 7, 2023 by Allen Williams

Despite fierce resistance from pharmaceutical titans and a flurry of lawsuits aimed at thwarting the process, the Centers for Medicare and Medicaid Services (CMS) is … Read more

GAO Urges Vigilant CMS Oversight: Keep a Close Watch on Drug Rebates and Their Impact on Medicare’s Financial Health

September 7, 2023 by Allen Williams

In the complex world of pharmaceuticals and healthcare, a recent report from the Government Accountability Office (GAO) has unveiled a startling reality: while rebates handed … Read more

Beam Breaks Ground with Pioneering Study: Unleashing Cutting-Edge Allogeneic, Base-Edited CAR-T Therapy in Early-Stage Trial

September 7, 2023 by Allen Williams

On a mission to redefine cancer treatment, Beam Therapeutics marked a major milestone as they administered the first dose of BEAM-201 to a courageous patient. … Read more

Moderna’s Breakthrough: Enhanced COVID-19 Vaccine Proven Highly Effective Against Emerging Variants

September 7, 2023 by Allen Williams

Moderna Unveils Game-Changing Update: COVID-19 Vaccine Packs a Punch Against New Variants! In a groundbreaking development, Moderna has revealed that its latest vaccine iteration is … Read more

Nimbus Scores Staggering $210 Million in Private Funding, Riding High After Game-Changing $4 Billion Takeda Partnership

September 7, 2023 by Allen Williams

Nimbus Therapeutics is making waves in 2023 with a whopping $210 million cash infusion to drive its cutting-edge small-molecule medicine research. This funding surge is … Read more

FDA’s Surprise Decision: AstraZeneca’s Ultomiris Faces Setback in Expanding Its Reach for NMOSD Treatment

September 7, 2023 by Allen Williams

In a surprising twist, the FDA has slammed the brakes on AstraZeneca’s ambitious plans to expand the horizons of its revolutionary drug, Ultomiris (ravulizumab-cwvz). The … Read more

Olema Oncology Secures a Potent Funding Boost of Up to $180 Million

September 6, 2023 by Allen Williams

Olema Oncology Gains Impressive $180 Million Boost in Combined Financing SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: … Read more

Alteogen’s Tergase® Shines with Outstanding Immunogenicity Profile in Breakthrough Injection

September 6, 2023 by Allen Williams

Alteogen’s Tergase® Breaks Ground with Zero Immunogenicity in Clinical Triumph DAEJEON, South Korea, September 5, 2023 – Brace yourselves for a medical marvel! Alteogen Inc. … Read more

Inmagene Welcomes Financial Maestro David Topper as New CFO

September 6, 2023 by Allen Williams

San Diego, September 5, 2023 – Inmagene Biopharmaceuticals, a trailblazing clinical-stage biotech firm dedicated to pioneering therapies for immunological and inflammatory diseases, has just scored … Read more

Crossject Triumphs: Secures European and U.S. Manufacturing Audits for ZENEO® Midazolam in Treating Epileptic Seizures

September 6, 2023 by Allen Williams

Crossject Achieves Manufacturing Milestones: Gains ISO Certifications, FDA Audit Readiness, and ANSM Authorization Dijon, France, September 5, 2023 – Crossject (ISIN: FR0011716265; Euronext: ALCJ), the … Read more

Ascletis: Front and Center at the Prestigious Morgan Stanley 21st Annual Global Healthcare Conference

September 6, 2023 by Allen Williams

HANGZHOU and SHAOXING, China, Sept. 4, 2023 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) is set to make waves as it steps onto the … Read more

Agilent Appoints Visionary Leader Philip Binns to Helm Life Sciences and Applied Markets Group

September 6, 2023 by Allen Williams

SANTA CLARA, Calif.–(BUSINESS WIRE)– Agilent Technologies, Inc. (NYSE: A) has just unveiled an exciting new chapter in its leadership team with the appointment of Philip … Read more

Novartis Joins the Battle: Lawsuits Mount Against IRA Drug Negotiation Program

September 6, 2023 by Allen Williams

“Novartis Takes a Stand: Files Lawsuit Against Health Department Over Drug Price Negotiation Program” In a bold move, Novartis has entered the legal fray by … Read more

Breakthrough Triumph: Genmab and Seagen Secure Late-Stage Win Against Metastatic Cervical Cancer

September 6, 2023 by Allen Williams

In a significant development, Genmab and Seagen have unveiled interim data from the Phase III innovaTV 301 trial, showcasing the remarkable potential of their antibody-drug … Read more

Breaking News: Novartis Fast-Tracks Sandoz Spin-Off, With Completion Date Set for October 4th

September 6, 2023 by Allen Williams

In a strategic move that’s been eagerly anticipated, Novartis has officially given the green light to the spin-off of its generics and biosimilars powerhouse, Sandoz. … Read more

Illumina’s Bold Move: Agilent Executive Takes the Helm Amidst Company’s Thrilling Challenges

September 6, 2023 by Allen Williams

After months of corporate turbulence and high-stakes battles, Illumina has placed its bets on a new leader, Jacob Thaysen, who will step into the role … Read more

Revolutionary Partnership: Novozymes and Bactolife Unite to Combat Post-Weaning Pig Woes, Slashing Antibiotics and Boosting Piglet Health!

September 5, 2023 by Allen Williams

Breaking Barriers in Swine Health: Novozymes and Bactolife Forge a Powerful Alliance to Tackle Post-Weaning Diarrhea in Piglets and Transform the Antibiotic Landscape! Copenhagen, Denmark … Read more

Revolutionizing Alzheimer’s Diagnosis: Rapid and Precise Detection Enabled by Novel Biomarker Tests

September 5, 2023 by Allen Williams

Before groundbreaking therapies for Alzheimer’s disease gained approval, the concept of biomarker tests remained on the periphery. However, a new dawn is breaking in the … Read more

Revolutionary GLP-1 Drugs Offer Early Glimmer of Hope in the Fight Against Alzheimer’s Disease

September 5, 2023 by Allen Williams

In the dynamic realm of biopharma, GLP-1 receptor agonists are blazing a trail. Originally designed to combat type 2 diabetes and obesity, these remarkable drugs … Read more

Revolutionizing Complement Component 5 Inhibition: Rallybio Unveils Phase 1 Single Ascending Dose Data for RLYB116

September 5, 2023 by Allen Williams

Breaking Barriers in Disease Treatment: RLYB116’s Remarkable Journey NEW HAVEN, Conn.–(BUSINESS WIRE)– Rallybio Corporation (Nasdaq: RLYB), a trailblazing biotech firm dedicated to transforming the lives … Read more

Medivir Breaks Ground with Exciting Interim Results: First Complete Response in Phase 1b/2a HCC Study Combining Fostrox and Lenvima

September 5, 2023 by Allen Williams

Medivir Breaks New Ground: First Complete Response in Phase 1b HCC Study with Fostrox and Lenvima STOCKHOLM, Sept. 4, 2023 /PRNewswire/ — Medivir AB (Nasdaq … Read more

Groundbreaking Milestone: Oncorena Administers First Dose of ONC175 (orellanine) in Clinical Trial for Metastatic Renal Cancer and Dialysis Patients at Karolinska University Hospital in Stockholm, Sweden

September 5, 2023 by Allen Williams

LUND, Sweden, Sept. 4, 2023 /PRNewswire/ — Oncorena, the vanguard of medical innovation, is thrilled to announce a remarkable milestone—the first patient has received treatment … Read more

SciBase Welcomes Seasoned Dermatology Executive to Bolster its U.S. Team

September 5, 2023 by Allen Williams

STOCKHOLM, Sept. 4, 2023 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a pioneering developer of augmented intelligence-based solutions for skin disorders, is thrilled to … Read more

Ligand Pharmaceuticals Unveils Exciting Inducement Grant in Accordance with NASDAQ Listing Rule 5635(c)(4) – Marking a Milestone on September 02, 2023

September 5, 2023 by Allen Williams

SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has taken a bold step towards embracing fresh talent. On September 1, 2023, the Human Capital Management … Read more

Fresenius Kabi and AABB Unveil the Thrilling Kickoff of the 18th Annual Blood Collectors Week: September 3-9, 2023 – Get Ready to Make a Life-Saving Impact!

September 5, 2023 by Allen Williams

Championing Unsung Heroes of Healthcare: Fresenius Kabi and AABB Illuminate the 18th Annual Blood Collectors Week, September 3-9, 2023 LAKE ZURICH, Ill. & BETHESDA, Md.–(BUSINESS … Read more

Groundbreaking Alliance: ICPO Foundation and NTP Radioisotopes SOC Ltd. Join Forces to Elevate Education Standards Globally and Spearhead Thriving Theranostics Centers Throughout Africa

September 5, 2023 by Allen Williams

Breaking Boundaries in Cancer Care: ICPO Foundation and NTP Radioisotopes SOC Ltd. Join Hands for a Transformative Collaboration In a groundbreaking announcement from WIESBADEN, Germany, … Read more

Shaping the Future: IQVIA’s Visionary CEO, Ari Bousbib, to Inspire at the Morgan Stanley Annual Global Healthcare Conference on September 12, 2023!

September 4, 2023 by Allen Williams

Breaking Barriers: IQVIA’s Visionary Leader, Ari Bousbib, Takes the Stage at the Morgan Stanley Annual Global Healthcare Conference in New York City! RESEARCH TRIANGLE PARK, … Read more

Charting the Future: Amicus Therapeutics Takes the Spotlight at Key Investor Conferences in September 2023!

September 4, 2023 by Allen Williams

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) – Get ready to be inspired as Amicus Therapeutics, Inc. (Nasdaq: FOLD) makes its mark on the global healthcare … Read more

Breaking Boundaries: Integra LifeSciences Takes Center Stage at the 2023 Wells Fargo Healthcare Conference!

September 4, 2023 by Allen Williams

PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) – Get ready to dive into the future of healthcare with Integra LifeSciences Holdings Corporation (NASDAQ: IART), a … Read more

Unlocking the Future: MustGrow Awards RSUs and DSUs to Drive Innovation!

September 4, 2023 by Allen Williams

“Empowering Visionaries: MustGrow Rewards Trailblazers with RSUs and DSUs” Saskatoon, Saskatchewan – September 1, 2023 – MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0), … Read more

Breaking News: Relief Therapeutics Gears Up for the Spotlight at the Prestigious H.C. Wainwright 25th Annual Global Investment Conference!

September 4, 2023 by Allen Williams

GENEVA, SWITZERLAND / ACCESSWIRE / September 1, 2023- Get ready for a dose of innovation and vision as Relief Therapeutics Holding SA (SIX: RLF) (OTCQB: … Read more

Mark Your Calendars: Kiora Pharmaceuticals Reschedules Special Stockholders Meeting to September 27th!

September 4, 2023 by Allen Williams

“Kiora Pharmaceuticals: Shaping the Future with Your Vote – Special Meeting Rescheduled to September 27!” Encinitas, California – September 1, 2023 – Kiora Pharmaceuticals, Inc. … Read more

Welcome Aboard! Leslie McDonnell Joins Mölnlycke’s Distinguished Board of Directors

September 4, 2023 by Allen Williams

Meet the Newest Star on Mölnlycke’s Board: Leslie McDonnell Takes the Helm” GOTHENBURG, Sweden, Sept. 1, 2023 – Mölnlycke AB welcomes a dynamic addition to … Read more

Get Ready for Action: Exact Sciences Takes the Stage at the Must-Attend Investor Conference of September 2023!

September 4, 2023 by Allen Williams

Breaking News from Madison, Wisconsin! Exact Sciences Corp. (Nasdaq: EXAS), the trailblazing leader in cancer screening and diagnostic tests, is gearing up for an electrifying … Read more

Breaking News: United Therapeutics Corporation Takes Center Stage at the Prestigious Morgan Stanley 21st Annual Global Healthcare Conference!

September 4, 2023 by Allen Williams

Exciting News from Silver Spring, MD, and Research Triangle Park, NC! United Therapeutics Corporation (Nasdaq: UTHR), a dynamic public benefit corporation, is set to make … Read more

Exciting Developments: Dr. Hitto Kaufmann Takes the Helm as Chief Scientific Officer at Hansa Biopharma

September 4, 2023 by Allen Williams

In a groundbreaking announcement from Lund, Sweden, on September 1, 2023, Hansa Biopharma, also known as ‘Hansa’ on the Nasdaq Stockholm under the symbol HNSA, … Read more

Guardant Health Unveils Exciting Progress in COBRA Study and Reinforces Trust in MRD Test

September 2, 2023 by Allen Williams

Palo Alto, CA – Guardant Health Inc. (Nasdaq: GH), pioneers in precision oncology, has unveiled a bold statement regarding the conclusion of the COBRA study, … Read more

Globus Medical and NuVasive Unite Forces in Exciting Merger!

September 2, 2023 by Allen Williams

Globus Medical and NuVasive: A Game-Changing Merger for Musculoskeletal Innovation In a landmark move, Globus Medical, Inc. (NYSE: GMED), a trailblazing musculoskeletal solutions company, has … Read more

Defying the Odds: GRI-0621 Offers Hope in the Battle Against IPF’s Grim Survival Statistics

September 2, 2023 by Allen Williams

Unlocking the Mystery of IPF: A Breathless Journey into the Enigmatic World of Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA / ACCESSWIRE / September 1, … Read more

Hugel Makes a Comeback: Resubmission of Letybo Botulinum Toxin BLA to the U.S. FDA

September 2, 2023 by Allen Williams

Hugel’s Grand Comeback: Letybo Botulinum Toxin Aims for FDA Approval in Q1 2024 SEOUL, South Korea, Sept. 1, 2023 /PRNewswire/ — Hugel, the global leader … Read more

Demanding Transparency: Lawmakers Grilling Lilly, Novo, and Sanofi on Insulin Aid Initiatives

September 2, 2023 by Allen Williams

Senators Demand Clarity: Lilly, Novo Nordisk, and Sanofi Under Scrutiny for Insulin Assistance Programs In a quest for transparency, U.S. Senators Maggie Hassan and Tina … Read more

Revolutionary Milestone: BioNTech and DualityBio Forge Ahead to Phase III with ADC for HER2-Low Breast Cancer

September 2, 2023 by Allen Williams

BioNTech’s Bold Move: ADC Gears Up for Phase III Battle in Breast Cancer Arena In a strategic move to challenge industry giants like AstraZeneca and … Read more

Alvotech’s Bold Bid: Second Attempt at FDA’s Seal of Approval for Humira Biosimilar Interchangeability

September 2, 2023 by Allen Williams

Alvotech’s Brave Bid for FDA Recognition: AVT02’s Quest for Biosimilar Glory In a bold move, Alvotech has resubmitted its Biologics License Application to the FDA, … Read more

COVID Booster Dreams Shattered: Bavarian Nordic Abandons Plans Post Lackluster Phase III Outcomes

September 2, 2023 by Allen Williams

Bavarian Nordic Abandons COVID Booster as New Variants Steal the Spotlight In a dramatic turn of events, Danish company Bavarian Nordic is bowing out of … Read more

Amgen’s $27.8B Horizon Deal Gets Green Light: FTC Agreement Paves the Way

September 2, 2023 by Allen Williams

2022’s Biggest Biotech Showdown: Amgen-Horizon Deal Gets FTC’s Nod In a thrilling twist, the Federal Trade Commission (FTC) has given the green light to the … Read more

Breaking News: Amgen-Horizon Partnership Gains Momentum, Top 10 Medications Enter IRA Price Talks, Workforce Changes, and More Unveiled!

September 2, 2023 by Allen Williams

In a whirlwind week of regulatory developments, the stage was set for high-stakes battles in the pharmaceutical world. On Friday, the Federal Trade Commission granted … Read more

Cleveland Diagnostics Unveils Prostate Cancer Awareness Blitz: Get Ready for the ‘A PSA on PSA’ Month!

August 31, 2023 by Allen Williams

“Empowering Change: Cleveland Diagnostics’ Dynamic Prostate Cancer Campaign Puts ‘A PSA on PSA’” CLEVELAND, August 30, 2023— Brace for impact as Cleveland Diagnostics, the vanguard … Read more

Ionis: Unveiling Exciting Insights! Get Ready for a Thrilling Showcase at the Upcoming September 2023 Investor Conferences

August 31, 2023 by Allen Williams

CARLSBAD, Calif., Aug. 30, 2023 /PRNewswire/ — Igniting Insights: Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is Set to Ignite Investor Conversations at Prestigious September 2023 Conferences … Read more

Mark Your Calendars: Ginkgo Bioworks Unveils Thrilling Investor Day Set for October 3rd, 2023

August 31, 2023 by Allen Williams

BOSTON, Aug. 30, 2023 /PRNewswire/ — Brace yourselves for an electrifying convergence of innovation! Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), the architect of an … Read more

Pfizer and BioNTech Throw Down the Gauntlet: Battle of Titans as They Challenge Moderna’s COVID-19 Patents at USPTO

August 31, 2023 by Allen Williams

“Rivalry of Titans: Pfizer and BioNTech Throw Down the Gauntlet, Challenging Moderna’s COVID-19 Patents” In a gripping showdown that could reshape the landscape of COVID-19 … Read more

FibroGen’s Tough Luck Persists: Phase III DMD Trial Disappointment Strikes Again

August 31, 2023 by Allen Williams

“FibroGen’s Bumpy Ride Continues: Setback in Phase III DMD Trial Sends Stocks Tumbling” In a disheartening blow, FibroGen unveiled disappointing results on Tuesday, revealing that … Read more

FDA’s Startling Move: Outlook’s Bold Bid for Wet AMD Treatment Rebuffed with a Resounding Response Letter

August 31, 2023 by Allen Williams

“FDA Delivers Stunning Blow: Outlook’s Ambitious Quest for Wet AMD Treatment Thwarted, Shares Plummet” In a surprising turn of events, the FDA cast a shadow … Read more

Revolutionizing the Fight Against Obesity: Novo’s $500M Leap into Embark Biotech to Supercharge Pipeline

August 31, 2023 by Allen Williams

Amidst the sizzling momentum of the obesity market, Novo Nordisk is making strategic waves yet again. In a bold move announced on Wednesday, the Danish … Read more

Bridge the Skills Gap: Unlocking the Future of Cell and Gene Therapies

August 31, 2023 by Allen Williams

“Unlocking the Future: Navigating the Skills Gap in Cell and Gene Therapies” Step into the realm of cell and gene therapies, a realm ablaze with … Read more

Unlocking Wisdom: Embracing Lessons with Franz-Werner Haas

September 2, 2023August 31, 2023 by Allen Williams

Navigating the labyrinth of cause and effect to show a young mind how present choices intertwine with the future is a boundless challenge. For Franz-Werner … Read more

Embracing the Future: Draft Guidances Pave the Way for Legitimized Decentralized Trials by Regulators

September 2, 2023August 31, 2023 by Allen Williams

Venturing into new technological territories is often met with the challenge of uncertain regulations, and this holds particularly true for early adopters. In the dynamic … Read more

Embarking on a Trailblazing Journey: Celularity and Regeneron Join Forces in a Multi-Year Research Collaboration Services Agreement

September 2, 2023August 30, 2023 by Allen Williams

“Unlocking the Future of Cell Therapies: Celularity Teams Up with Regeneron in Groundbreaking Research Partnership FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) — Brace … Read more

Fosun Pharma Unveils Exciting 2023 Interim Results: Igniting Innovation, Transforming, and Crafting an Optimal Product Landscape

August 30, 2023 by Allen Williams

SHANGHAI, Aug. 29, 2023 /PRNewswire/ — Setting the Stage for Progress: Fosun Pharma’s Thrilling 2023 Interim Results Unveiled! On August 29, 2023, Shanghai Fosun Pharmaceutical … Read more

Exciting News: US FDA Grants Priority Review Designation to Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Treatment

September 2, 2023August 30, 2023 by Allen Williams

Major Breakthrough: Zealand Pharma’s Dasiglucagon Gains Priority Review by US FDA for Innovative Treatment of Congenital Hyperinsulinism Copenhagen, Denmark, August 30, 2023 – Zealand Pharma … Read more

Breaking News: Asieris Clears Major Hurdle for Innovative Ulcerative Colitis Drug!

August 30, 2023 by Allen Williams

SHANGHAI, Aug. 30, 2023 /PRNewswire/ — Get ready for a groundbreaking stride in the realm of medical progress as Asieris Pharmaceuticals (688176), a global biopharma … Read more

Unveiling Progress: BioInvent’s Exciting Mid-Year Update for 2023

September 2, 2023August 30, 2023 by Allen Williams

Breaking Boundaries in Cancer Treatment: A Glimpse into BioInvent’s Triumphs LUND, SWEDEN / ACCESSWIRE / August 30, 2023 / Brace for Impact: BioInvent International (STO:BINV) … Read more

Breaking Records: Akeso Unveils 2023 Interim Results – From First Profits to Soaring Sales of PD-1/CTLA-4 Bispecific Marvel and Fast-Track Glimpse into PD-1/VEGF Priority Review

August 30, 2023 by Allen Williams

Unleashing Triumph: Akeso’s 2023 Interim Results Soar with Phenomenal Growth HONG KONG, Aug. 29, 2023 /PRNewswire/ — Brace for Impact: Akeso (9926. HK) is rewriting … Read more

Breaking New Frontiers: InxMed Greenlit to Embark on China Phase I Clinical Trial for OMTX705 – A Trailblazing ADC Aimed at FAP

August 30, 2023 by Allen Williams

NANJING, China, Aug. 29, 2023 /PRNewswire/ — Brace for Impact: InxMed, a beacon of innovation in the biotech arena, is making waves yet again. Focused … Read more

Elevating Patient Care: Unveiling Next-Level Innovations in A Series Anaesthesia Systems by Mindray, Redefining Safety and Efficiency

August 30, 2023 by Allen Williams

Breaking Ground in Healthcare Innovation: SHENZHEN, China, Aug. 29, 2023 — Mark your calendars as Mindray (SZSE: 300760), a vanguard in cutting-edge medical solutions, proudly … Read more

Mark Your Calendar: Be Front and Center as argenx Takes the Stage at Exciting Investor Conferences in September 2023!

August 30, 2023 by Allen Williams

Unlocking Boundless Potential: Join us on an Exciting Journey with argenx in Amsterdam, the Netherlands (Euronext & Nasdaq: ARGX). Brace yourself for a remarkable September … Read more

Revolutionizing Southeast Asia’s Research Landscape: BioSkryb Genomics Joins Forces with Research Instruments Pte Ltd to Introduce Cutting-Edge Single-Cell Technologies to Singapore and Beyond!

August 30, 2023 by Allen Williams

Unleashing the Future of Research: BioSkryb Genomics and Everlife-RI Join Forces to Illuminate Southeast Asia with Cutting-Edge Single-Cell Multiomics Solutions DURHAM, N.C.–(BUSINESS WIRE)– In a … Read more

Unveiling Breakthroughs: Alentis Therapeutics Takes the Stage at the Prestigious ERS International Congress

August 30, 2023 by Allen Williams

Breaking Frontiers: ALE.F02’s Intriguing Quest to Transform Pulmonary Fibrosis Treatment BASEL, Switzerland–(BUSINESS WIRE)– Brace yourself for a revelation that could reshape medical history! Alentis Therapeutics, … Read more

Setting the Stage: Bausch + Lomb Gears Up to Shine at the 2023 Wells Fargo Healthcare Conference

August 30, 2023 by Allen Williams

Visionary Moves: Bausch + Lomb’s CEO Brent Saunders Takes Center Stage at the 2023 Wells Fargo Healthcare Conference VAUGHAN, Ontario–(BUSINESS WIRE)– Get ready for a … Read more

Breaking Ground: DZD Secures SBIR Grant to Pioneer Microbiome Diagnostics Revolution

August 30, 2023 by Allen Williams

“Unleashing Innovation: DZD Scores Major Win for Safer Fecal Microbiota Transplants with SBIR Funding BOSTON, Aug. 29, 2023 /PRNewswire/ — Brace yourself for a game-changing … Read more

Steering Towards Excellence: Catalent Unveils Ambitious Governance Upgrades and Innovative Ventures to Unleash Value

August 30, 2023 by Allen Williams

“Catalent Unveils Strategic Evolution: New Board Appointments, Transformational Initiatives, and a Vision for Long-Term Value” SOMERSET, N.J.–(BUSINESS WIRE)– The stage is set for transformation as … Read more

Unlocking Hope: Lilly’s Breakthrough Cholesterol Pill Shines Bright in Early Phase I Triumph

August 30, 2023 by Allen Williams

“Unveiling a Health Revolution: Eli Lilly’s Bold Leap with Cholesterol-Busting Pill, Muvalaplin, in Groundbreaking Phase I Trial” In the world of medical exploration, where breakthroughs … Read more

Disheartening Twist: Novocure’s Ambitious Stride in Ovarian Cancer Falls Short in Phase III Showdown

August 30, 2023 by Allen Williams

“Whispers of Promise Meet Unexpected Turn: Novocure’s Ovarian Cancer Journey Takes an Unexpected Twist in Phase III INNOVATE-3 Trial” In the high-stakes world of medical … Read more

FDA Grants Green Light to BMS, Unleashing Reblozyl’s Potential as a Game-Changer

September 2, 2023August 30, 2023 by Allen Williams

“Charting a Bold Course: BMS Expands Reblozyl’s Arsenal with FDA’s Stamp of Approval” Bristol Myers Squibb is on a resolute march toward its grand vision … Read more

Breaking Through: CMS Unveils Groundbreaking List of 10 Medications Set for Medicare Price Talks

August 30, 2023 by Allen Williams

“Medicare’s Pharmaceutic Showdown: The First 10 Prescription Mavericks Stepping into the Ring of Price Negotiation” In a theatrical twist that has the pharmaceutical world buzzing, … Read more

Unleashing Biotech Potential: 5 Unique Funding Paths for Public Emergence

August 30, 2023 by Allen Williams

I might be revealing a touch of my age, but I’ve weathered the storm through four jaw-dropping microcap meltdowns: the tumultuous dance of 1987, the … Read more

Unrelenting Recalls and Shutdowns Exacerbate the Growing Drug Shortage Dilemma

August 30, 2023 by Allen Williams

July reached its crescendo with a surprising twist as Lupin Pharmaceuticals, a major player in the drug production saga, issued yet another recall. This time, … Read more

Sparkling September Ahead: Axonics Ready to Shine at 2023 Investor Conferences

August 26, 2023 by Allen Williams

Mark Your Calendar: Join the Buzz with Axonics at September’s Exciting Investor Conferences! IRVINE, Calif.–(BUSINESS WIRE)– Get ready to dive into the world of cutting-edge … Read more

Breaking Myths: Source Plasma Donations and Donor Well-Being

August 26, 2023 by Allen Williams

In a groundbreaking stride towards transparency, the Plasma Protein Therapeutics Association (PPTA) has unveiled its latest research revelation. This study, a meticulously conducted investigation titled … Read more

Diving into the Genetic Code: The Jackson Laboratory’s Breakthrough in Decoding 43 Human Y Chromosomes

August 26, 2023 by Allen Williams

Unveiling the Enigmatic Y Chromosome: A Leap in Understanding Human Evolution and Biology FARMINGTON, Conn., Aug. 24, 2023 /PRNewswire/ — A cryptic treasure trove of … Read more

Empowering Pain Relief: Medtronic’s Inceptiv™ Spinal Cord Stimulator Secures CE Mark Approval, Paving the Way for Innovative Chronic Pain Treatment

August 26, 2023 by Allen Williams

“Unveiling a New Era of Pain Relief: Medtronic’s Inceptiv™ SCS Revolutionizes Therapy with Innovative Closed-Loop Technology” Dublin, August 25, 2023—A groundbreaking chapter in pain management … Read more

Spectacular Surprise: Exelixis Halts Phase III Trial Prematurely as Neuroendocrine Tumor Benefits Shine

August 26, 2023 by Allen Williams

“Unexpected Triumph: Exelixis Breaks Convention, Halts Phase III CABINET Trial Early Due to Stunning Progress” In a stunning twist that sent ripples through the scientific … Read more

Navigating the UK’s Scientific Skills Challenge: Bridging the Gap

August 26, 2023 by Allen Williams

“Unveiling the Blueprint for the UK’s Journey to Scientific Supremacy: A Tale of Infrastructure and Expertise” In the wake of August’s leadership elections, a resounding … Read more

FDA Unlocks a New Era: Sandoz’s Biosimilar to Biogen’s MS Miracle, Tysabri, Receives Resounding Approval

August 26, 2023 by Allen Williams

“Breaking Barriers: FDA Greenlights Sandoz’s Tyruko, a Game-Changing Biosimilar to Biogen’s Tysabri” In a watershed moment for medical progress, the FDA has handed down a … Read more

Reshaping the Heart Health Landscape: Novo’s Wegovy Clinches Yet Another Cardio Triumph

August 26, 2023 by Allen Williams

“Novo Nordisk Unveils Yet Another Triumph: Wegovy’s Heart-Boosting Power Extends to Common Heart Failure” In a resounding symphony of medical achievement, Novo Nordisk, the Danish … Read more

Unveiling a Week of Medical Marvels: Wegovy’s Heart-Healthy Surprise, Biosimilars Gain Speed, and Much More

August 26, 2023 by Allen Williams

In the ever-evolving landscape of medical breakthroughs, few phrases carry as much weight as ‘wonder drug.’ Novo Nordisk’s Wegovy (semaglutide) is dancing dangerously close to … Read more

Promising Alliance Hits a Roadblock: Keytruda-Lenvima Phase III Trial for Head and Neck Cancer Comes to an End

August 26, 2023 by Allen Williams

“Collaborative Drug Quest Takes a Turn: Keytruda and Lenvima Combination Trial Dropped Following Phase III Disappointment” In a maze of medical exploration, two pharmaceutical trailblazers, … Read more

Recce Pharmaceuticals Takes Bold Step Forward: Administers First Doses in Phase I/II Clinical Trial of RECCE® 327, a Potential Breakthrough for Diabetic Foot Infections

August 25, 2023August 25, 2023 by Allen Williams

“Recce Pharmaceuticals Achieves Major Milestone: Administers First Doses in Game-Changing Clinical Trial of RECCE® 327, a Potential Revolution for Diabetic Foot Infections” SYDNEY, Australia, Aug. … Read more

Breakthrough in Diabetes Treatment: Abata Therapeutics Unveils ABA-201, a Cutting-Edge Treg Cell Therapy for Type 1 Diabetes

August 25, 2023August 25, 2023 by Allen Williams

“Revolutionizing Diabetes Treatment: Abata Therapeutics Unveils ABA-201, a Groundbreaking Treg Cell Therapy for Type 1 Diabetes WATERTOWN, Mass.–(BUSINESS WIRE)–In a landmark breakthrough, Abata Therapeutics is … Read more

Breaking News: AEON Biopharma’s Innovation Takes Flight as USPTO Grants Patent for Revolutionary Migraine Treatment with Botulinum Toxins

August 25, 2023August 25, 2023 by Allen Williams

“Game-Changer Alert: AEON Biopharma Secures Vital Patent for Breakthrough Migraine Treatment” IRVINE, Calif., Aug. 24, 2023 – Brace yourselves for a groundbreaking moment in medical … Read more

Unveiling the Unseen: Rune Labs and Aspen Neuroscience Join Forces to Decode Parkinson’s Disease Symptoms for Groundbreaking Trial Screening

August 25, 2023August 25, 2023 by Allen Williams

“Unlocking Insights: Rune Labs and Aspen Neuroscience Unite to Pioneer Breakthrough Parkinson’s Research” SAN FRANCISCO—In a remarkable convergence of innovation, Rune Labs and Aspen Neuroscience … Read more

Unlocking New Horizons: Xcell Biosciences and Labcorp Hit Milestone Breakthroughs in Dynamic Cell and Gene Therapy Collaboration

August 25, 2023August 25, 2023 by Allen Williams

“Unleashing Breakthroughs: Xcell Biosciences and Labcorp’s Dynamic Partnership Elevates Cell and Gene Therapy Frontiers” SAN FRANCISCO—In a symphony of scientific innovation, Xcell Biosciences Inc. (Xcellbio) … Read more

Breaking Boundaries: Everest Medicines Celebrates Nefecon® Milestone with Macao’s Drug Application Approval for Primary IgA Nephropathy Treatment

August 25, 2023August 25, 2023 by Allen Williams

SHANGHAI, Aug. 24, 2023 /PRNewswire/ — Embarking on a Pioneering Journey: Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a trailblazing biopharmaceutical powerhouse, has unveiled … Read more

Medical Milestone: FDA Greenlights Historic Biosimilar for Multiple Sclerosis Treatment

August 25, 2023August 25, 2023 by Allen Williams

SILVER SPRING, Md., Aug. 24, 2023 /PRNewswire/ — A Remarkable Leap Forward: Today, the U.S. Food and Drug Administration has granted its seal of approval … Read more

Strategic Shift: AbbVie Drops Two Promising Early-Stage Cancer Ventures from Development Pipeline

August 25, 2023August 25, 2023 by Allen Williams

“Plot Twist: AbbVie Shakes Up Strategy, Bids Farewell to Two Cutting-Edge Cancer Ventures” In a surprising turn of events, AbbVie has set the stage for … Read more

Triumph Unveiled: Roche’s Divarasib Achieves Breakthrough in Phase I Against Resilient KRAS-Mutated Solid Tumors

August 25, 2023August 25, 2023 by Allen Williams

“Unleashing Hope: Roche’s Divarasib Shines in Battle Against Stubborn KRAS-Mutated Solid Tumors” In a thrilling revelation, Roche’s Genentech has unveiled a potential game-changer in the … Read more

Massive $500 Million Offer: Royalty Pharma Set to Acquire Royalty Rights for Ferring’s Cutting-Edge Gene Therapy

August 25, 2023August 25, 2023 by Allen Williams

“Swiss Marvel: Ferring Pharmaceuticals Surges as Royalty Pharma Invests a Staggering $500 Million in Revolutionary Gene Therapy” In a groundbreaking move, Ferring Pharmaceuticals, based in … Read more

Charting Future Ventures: Pharming Group’s Exciting Stint at Investor Conferences this September!

August 24, 2023 by Allen Williams

“From Leiden to the World: Pharming Group Gears Up for a Transatlantic Conference Spree!” LEIDEN, The Netherlands, Aug. 24, 2023 /PRNewswire/ — Brace yourselves for … Read more

Fireside Chat Sparks Innovation: CancerVAX CEO Engages in Dynamic Dialogue on Cancer Immunotherapy with UCLA’s Trailblazing Physician-Scientist

August 24, 2023August 24, 2023 by Allen Williams

“Unveiling a Maverick’s Odyssey: CancerVAX CEO Dives Deep into Conversation with UCLA’s Trailblazing Cancer Crusader, Dr. Steven Jonas” LEHI, Utah, Aug. 24, 2023 (GLOBE NEWSWIRE) … Read more

Revolutionizing AML Treatment: XNK Therapeutics and Karolinska University Hospital Join Forces in Groundbreaking Research Collaboration

August 24, 2023August 24, 2023 by Allen Williams

“A Bold Leap Towards Conquering Leukemia: XNK Therapeutics Joins Hands with Karolinska University Hospital to Pioneer Breakthrough Research!” HUDDINGE, Sweden, Aug. 24, 2023 /PRNewswire/ — … Read more

Unveiling Innovation: Emerging Venture Takes Center Stage with Rapid Immunodiagnostic Lateral Flow Tests

August 24, 2023August 24, 2023 by Allen Williams

“San Diego, CA – August 24, 2023 – A New Dawn in Diagnostics: Gold Colloid, Co. Emerges as a Trailblazer in Rapid Immunodiagnostic Lateral Flow … Read more

Strategic Shift: J&J Reduces Research and Development Efforts in Netherlands Infectious Disease and Vaccine Division

August 24, 2023August 24, 2023 by Allen Williams

“J&J Initiates Strategic Shift: Infectious Disease and Vaccine Unit Undergoes Transformation” In a strategic maneuver that’s capturing industry attention, Johnson & Johnson is orchestrating a … Read more

Bold Leap: CVS Health Ventures into Biosimilars Arena with Cordavis Subsidiary Unveiling

August 24, 2023August 24, 2023 by Allen Williams

“Revolutionizing Healthcare: CVS Health Unveils Cordavis, its Biosimilars Marvel” A seismic shift has erupted in the realm of consumer healthcare, as CVS Health steps onto … Read more

Perspective: Advocating for Employer Branding in the Biotech Industry

August 24, 2023August 24, 2023 by Allen Williams

In the ever-evolving realm of biotechnology, where breakthroughs are a daily currency, an unexpected blind spot has emerged: the realm of employer branding. While the … Read more

Collaborative Efforts by Bob Dagher Lead BrainStorm to Successful Completion

August 24, 2023 by Allen Williams

From his formative years in Lebanon, where he once led his childhood soccer squad, Bob Dagher’s passion for teamwork found an unexpected echo in his … Read more

Vaxxas Wins $3.67 Million Boost from Wellcome Foundation to Revolutionize Typhoid Vaccination with Needle-Free Patch!

August 24, 2023 by Allen Williams

Breaking Boundaries: Vaxxas Joins Forces with Wellcome and SK Bioscience to Supercharge Typhoid Vaccination! In a groundbreaking collaboration, Vaxxas, the trailblazing biotech company behind an … Read more

Royalty Pharma and Ferring Pharmaceuticals Seal $500 Million Deal for Revolutionary Intravesical Gene Therapy Adstiladrin®!

August 24, 2023 by Allen Williams

Exciting Partnership Unleashed: Royalty Pharma’s $500 Million Boost for Ferring’s Breakthrough Bladder Cancer Therapy! In a groundbreaking collaboration, Royalty Pharma and Ferring Pharmaceuticals have ignited … Read more

Atrion Corporation Surprises Investors with Augmented Quarterly Cash Dividend – August 22, 2023

August 23, 2023 by Allen Williams

Spark of Excitement: Atrion Corporation Amps Up Quarterly Cash Dividend to $2.20 Per Share – August 22, 2023 ALLEN, Texas—In a resounding declaration of value … Read more

Coherus BioSciences Unveils Exciting New Employment Inducement Grants – August 22, 2023

August 23, 2023 by Allen Williams

In an exciting move, Coherus BioSciences, headquartered in REDWOOD CITY, Calif., made a significant announcement on August 22, 2023. The innovative biotech company (Nasdaq: CHRS) … Read more

Crafting a Future of Flawless Supply: Kinaxis Chosen by Fabbrica Italiana Sintetici (F.I.S.) for Masterful Planning

August 23, 2023 by Allen Williams

Unleashing Agility: Kinaxis® Powers Italian Pharmaceutical Trailblazer to Conquer Market Turbulence OTTAWA, Ontario–(BUSINESS WIRE)– In a symphony of innovation, Kinaxis® Inc. (TSX: KXS), the maestro … Read more

Revolutionary LifePort Liver Transporter Triumphs: Crowned Winner of Fast Company’s 2023 Innovation by Design Award in the ‘Health’ Category!

August 23, 2023 by Allen Williams

Embracing over a decade of groundbreaking Innovation by Design, the spotlight of 2023 falls on exceptional endeavors from industry giants like Adobe, PepsiCo, and Canva, … Read more

Pioneering Breakthroughs: Foundery Unveils Debut Biotech Venture Fund Igniting the Future of Immunotherapy Advancements

August 23, 2023 by Allen Williams

Unleashing Innovation: Foundery Sparks a Biotech Revolution, Linking Visionary Drug Development with Immune Discoveries SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace yourselves for … Read more

Epic Milestone Achieved: Grander Successfully Acquires Assets of PolarityTE, Inc.

August 23, 2023 by Allen Williams

A New Era Dawns: Grander’s Bold Leap Transforms into PolarityTE’s Private Vanguard SALT LAKE CITY, Aug. 22, 2023 /PRNewswire/ — Amidst a symphony of anticipation, … Read more

Embark on the Longeveron Journey: Join the Rights Offering Subscription Period Now!

August 23, 2023 by Allen Williams

Exciting Update from Longeveron: Embarking on a Journey to Transform Lives! MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace yourselves for groundbreaking news from Longeveron … Read more

Empowering Women’s Health: Myriad Genetics and Onsite Women’s Health Join Forces to Illuminate Breast Cancer Risk

August 23, 2023 by Allen Williams

“SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace for Impact: Myriad Genetics, the Vanguard of Genetic Exploration, and Onsite Women’s Health, Champions of … Read more

Revolutionary Boost: Advanced NanoTherapies (ANT) Clinches $4M Game-Changing Investment to Fast-Track SirPlux Duo’s Battle Against Coronary Artery Disease!

August 23, 2023 by Allen Williams

“Revolution Unleashed: ANT Triumphs with 10 Brave Hearts Leading the Charge in Breakthrough Trial!” LOS GATOS, Calif., Aug. 22, 2023 /PRNewswire/ — Brace yourselves for … Read more

Breaking News: Reflect Scientific Lands Major $200,000 Order for State-of-the-Art Blast Freezers from Leading Bio-Pharma Titan

August 23, 2023 by Allen Williams

OREM, Utah, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace yourselves for a frozen revolution as Reflect Scientific, Inc. (Symbol: RSCF), the reigning maestro of cutting-edge … Read more

Gathering of Pediatric Growth Experts: Exploring the World of Pediatric Growth Hormone Deficiency and Breakthrough Therapies

August 23, 2023 by Allen Williams

“Unlocking the Future of Pediatric Growth: Join the Virtual Webinar on September 5, 2023, at 11:00 AM Eastern Time!” AUSTIN, Texas, Aug. 22, 2023 (GLOBE … Read more

Boehringer Ingelheim Enters the Fray: Joins Legal Clash Over IRA Drug Pricing Rules

August 23, 2023 by Allen Williams

Boehringer Ingelheim has thrown down the gauntlet against the U.S. government, unleashing a legal battle to halt the Inflation Reduction Act’s drug price negotiation program. … Read more

Pioneering Win: FDA Greenlights Pfizer’s Breakthrough Maternal RSV Vaccine for Infant Protection

August 23, 2023 by Allen Williams

“Breaking Boundaries: FDA Greenlights Pfizer’s Revolutionary Maternal RSV Vaccine, Shielding Infants” In a remarkable stride forward, the FDA has granted approval to Pfizer’s groundbreaking Abrysvo … Read more

Navigating Ethics: Unveiling Industry Connections of Patient Advocacy Leaders and Executives

August 23, 2023 by Allen Williams

“Unmasking the Ties: Industry Influence Raises Alarms in Leading Patient Advocacy Organizations” A revealing spotlight has been cast upon the inner workings of top U.S. … Read more

Breaking Barriers: Fulcrum’s Sickle Cell Trial Breaks Free and Gains Momentum After Regulatory Hold

August 23, 2023 by Allen Williams

Unlocking Hope: Fulcrum’s Sickle-Cell Breakthrough Surges Forward as FDA Lifts Clinical Hold The tides of progress are in favor of Fulcrum Therapeutics as they charge … Read more

Teva’s Legal Symphony: A $225M Overture in DOJ Settlement for Generic Drug Price-Fixing

August 23, 2023 by Allen Williams

“Teva Pharmaceuticals Strikes a Legal Chord: Navigating the Labyrinth of Drug Price-Fixing Case” In a legal symphony that reverberates through the pharmaceutical world, Teva Pharmaceuticals … Read more

Unleashing Hope: Novavax’s Latest COVID Vaccine Breaks Chains, Confronting Emerging Subvariants Head-On

August 23, 2023 by Allen Williams

“Novavax’s Swift Reckoning: Defying Odds, Tackling Subvariants, and Forging Ahead with a Season of Hope” In the realm of COVID-19 battles, Novavax stands as a … Read more

Breakthrough Unveiled: Lilly’s Retevmo Achieves Remarkable Survival Triumph in Phase III Thyroid Cancer Trial

August 23, 2023 by Allen Williams

Eli Lilly Emerges Victorious in a Thrilling Showdown Against Thyroid Cancer: Retevmo Takes the Lead in High-Stakes RET-Mutant Battle In an electrifying twist within the … Read more

A Resounding Victory: Recor Medical and Otsuka Medical Devices Secure Green Light from FDA Advisory Committee for Paradisiacal Battle Against Hypertension

August 23, 2023 by Allen Williams

A Breakthrough Emerges: Recor Medical and Otsuka Medical Devices Secure FDA Panel’s Favor for Paradisiacal Hypertension Solution PALO ALTO, Calif.–(BUSINESS WIRE): Brace yourselves for a … Read more

Actimed Therapeutics Triumphs with £4.75M Boost in Series A Extension, Nearly Doubling Initial Proceeds

August 23, 2023 by Allen Williams

London, UK – August 22, 2023: Brace yourself for the remarkable tale of Actimed Therapeutics Ltd (“Actimed”), a UK-based trailblazer in the world of clinical … Read more

A New Chapter Unfolds: Dr. Felix Baader and Roland Diggelmann Join Berlin Heals’ Board, Embarking on the Grand Finale of CE Study”

August 22, 2023 by Allen Williams

Whispers of Innovation: A Symphony from Zurich’s Heart ZUG, Switzerland, August 22, 2023 /PRNewswire/ — Amidst the Echoing Chimes of Swiss Precision, Berlin Heals Holding … Read more

Shining Bright at EANM 2023 Congress: Actinium Pharma Takes Center Stage with Exciting Abstracts for Oral and Poster Presentation

August 22, 2023 by Allen Williams

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a trailblazer in the realm of targeted radiotherapies, has illuminated the spotlight with its latest announcement. Set against the … Read more

Venturing Beyond: Unveiling Satellos Bioscience Inc. on the TSX Exchange – A Glimpse from the Executive Suite

August 22, 2023 by Allen Williams

Diving into Innovation: Frank Gleeson, the Visionary CEO of Satellos Bioscine (TSXV: MSCL), Illuminates the Company’s Journey in a Captivating Conversation with TMX Group Unlocking … Read more

Breaking Through: JCO Oncology Practice Unveils Powerful Real-World Insights from Genomic Testing in Stage IV Non-Small-Cell Lung Cancer Patients

August 22, 2023 by Allen Williams

Unveiling the Puzzle: Breakthrough Insights from Integra Connect Illuminate the Path to Precision Cancer Care WEST PALM BEACH, Fla., Aug. 21, 2023 /PRNewswire/ — Brace … Read more

Soligenix: A Trail of Triumphs Unveiled Alongside Spectacular Q2 2023 Financial Results

August 22, 2023 by Allen Williams

Unveiling Triumphs from the Heart of Princeton: Soligenix’s Remarkable Journey and Q2 2023 Financial Feats PRINCETON, N.J., August 21, 2023 /PRNewswire/ – Brace yourself for … Read more

Rising to New Heights: Mark C. McKenna, Visionary in Healthcare, Takes Helm as Chairman of Apogee Therapeutics Board

August 22, 2023 by Allen Williams

“From Coast to Coast, a Visionary Voyage: Mark C. McKenna Anchors Apogee Therapeutics, Steering the Ship of Innovation” SAN FRANCISCO and WALTHAM, Mass., Aug. 21, … Read more

HUTCHMED’s Triumph: Sovleplenib Phase III ESLIM-01 Study Conquers Primary Immune Thrombocytopenia in China!

August 22, 2023 by Allen Williams

The exciting journey of discovery unfolded through a meticulously designed randomized, double-blind, controlled trial. This trailblazing effort successfully reached its primary endpoint, showcasing a remarkable … Read more

Unveiling the Future: Enzymit’s Deep Learning Paves the Way for Uncharted Biocatalysis Frontiers

August 22, 2023 by Allen Williams

“In a Stunning Leap, AI Breaks Ground in Enzyme Revolution, Sparking a New Era of Bioproduction” NESS ZIONA, Israel, Aug. 21, 2023 /PRNewswire/ — Enzymit, … Read more

Amicus Therapeutics Welcomes Simon Harford as Maestro of Finance

August 22, 2023 by Allen Williams

A Symphony of Progress: Amicus Therapeutics Welcomes Financial Maestro Simon Harford In a dynamic crescendo that reverberated across the biotech landscape, Amicus Therapeutics, Inc. (Nasdaq: … Read more

Unlocking the Future of Gene Editing: Breakthrough Study Unveils Turbocharged CRISPR-Cas9 Knock-In Power with Small-Molecule Inhibitor Duo

August 22, 2023 by Allen Williams

Revolutionizing Gene Editing: A Symphony of Innovation Unveiled by Promega Scientists Sparks New Era of Precision. MADISON, Wis.–(BUSINESS WIRE)– In a riveting chapter of scientific … Read more

Unveiling a New Chapter: Axogen, Inc. Ignites Innovation with Avance® Nerve Graft Processing Hub in Vibrant Dayton, Ohio

August 22, 2023 by Allen Williams

Unveiling a New Era: ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023. Amid a symphony of innovation and commitment, Axogen, Inc. (NASDAQ: AXGN), a trailblazer … Read more

Unlocking the Future: Krystal Biotech’s $100 Million Sale of a Priority Review Voucher

August 22, 2023 by Allen Williams

PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) — Brace yourself for a groundbreaking announcement from Krystal Biotech Inc. (NASDAQ: KRYS), a trailblazing biotech powerhouse on a … Read more

Unlocking Clues: GeneDx Reveals Breakthrough—Whole Exome and Genome Sequencing Slash Variants of Uncertain Significance (VUS) Compared to Multi-Gene Panels! Findings Featured in Genetics in Medicine

August 22, 2023 by Allen Williams

Unveiling Genomic Insights: GeneDx Sparks Transformation in Genetic Diagnosis STAMFORD, Conn., Aug. 21, 2023 — In a groundbreaking stride towards deciphering the genetic enigma, GeneDx … Read more

Charting New Horizons: Treace Medical Concepts Welcomes Nathan Minnich as Architect of Marketing Excellence, Senior Vice President

August 22, 2023 by Allen Williams

PONTE VEDRA’s New Maestro of Innovation: Treace Medical Concepts Welcomes Nathan Minnich as Sr. Vice President, Unleashing a New Era of Surgical Excellence PONTE VEDRA, … Read more

Embarking on the Odyssey: Apollon and MIT Join Forces to Forge the Future of Continuous Non-Invasive Glucose Monitoring Tech

August 22, 2023 by Allen Williams

Seoul’s MedTech Trailblazer, Apollon, Partners with MIT to Forge the Future of Non-Invasive Glucose Monitoring SEOUL, South Korea — In a daring fusion of minds … Read more

Enveric Biosciences Achieves a Milestone: Crafting the Future of Medicine with EB-373 for Accelerating Preclinical Advancements!

August 22, 2023 by Allen Williams

Breaking New Horizons: Enveric Biosciences (NASDAQ: ENVB) Ushers in a New Era of Healing in CAMBRIDGE, Mass. A Symphony of Innovation and Dedication Unveiled! Enveric … Read more

Exciting Milestone: FDA Greenlights Geron’s New Drug Application for Imetelstat, Marking a Leap Forward in Treating Lower Risk MDS

August 22, 2023 by Allen Williams

Turning the Tide: Geron’s Imetelstat Breakthrough Clears FDA Hurdle, Paving the Way for Innovative Treatment of Myelodysplastic Syndromes FOSTER CITY, Calif.–(BUSINESS WIRE)– The stage is … Read more

Triumphant Comeback: Roche and Exelixis’ Dynamic Drug Duo Secures Victory in Advanced Prostate Cancer Battle

August 22, 2023 by Allen Williams

Fusion of Innovation: Moderna Joins Forces with CARsgen Therapeutics to Forge a Powerful Duo Against Solid Tumor Cancers In an electrifying collaboration, Moderna and China’s … Read more

FDA Slaps Partial Clinical Hold Once More on Gilead’s Promising Magrolimab

August 22, 2023 by Allen Williams

Dramatic Twist: FDA Places Gilead’s Breakthrough Leukemia Drug, Magrolimab, on Clinical Hold Again In a surprising turn of events, the FDA has thrown another curveball … Read more

A Triumph Unveiled: CanariaBio Attains FDA’s Orphan Drug Designation for MAb-AR20.5, a Beacon of Hope in the Fight Against Pancreatic Cancer

August 21, 2023 by Allen Williams

A Triumph of Science: Breaking Barriers in Cancer Research as CanariaBio’s Innovator, MAb-AR20.5, Achieves Landmark Orphan Drug Designation for Pancreatic Cancer PYEONGTAEK, South Korea, Aug. … Read more

Exciting Horizons: Timber Pharmaceuticals Set to Join Forces with LEO Pharma in Landmark Acquisition

August 21, 2023 by Allen Williams

WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) — through the Vibrant Pulse of NewMediaWire — Brace yourselves for a groundbreaking alliance as Timber Pharmaceuticals, Inc. … Read more

Unveiling Progress: Phathom Pharmaceuticals Submits Compelling Six-Month Stability Data to Bolster New Drug Application for Erosive GERD Treatment

August 21, 2023 by Allen Williams

“FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) — Brace yourselves for groundbreaking news as Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a trailblazing biopharmaceutical powerhouse, strides … Read more

Precision Unleashed: Exactech Secures FDA Green Light for Next-Gen Activit-E™ Knee Replacement Polyethylene

August 21, 2023 by Allen Williams

In the vibrant city of Gainesville, where innovation knows no limits, a symphony of progress echoes. Hear the crescendo as Exactech, Inc. takes center stage … Read more

Revolutionizing Data Analysis: Empowering All with Scale Biosciences and Basepair in the World of Single Cell Sequencing

August 21, 2023 by Allen Williams

SAN DIEGO–(BUSINESS WIRE)–In a leap towards scientific advancement, Scale Biosciences, Inc. (aka ScaleBio), a trailblazer in single-cell sequencing technology, has unveiled an exciting partnership with … Read more

Embrace Timeless Beauty: Sentient’s Tixel Garners FDA Nod to Smooth Periorbital Wrinkles

August 21, 2023 by Allen Williams

Introducing a Revolution in Aesthetics: Transformative Care for the Delicate Eye Area PARK CITY, Utah, Aug. 21, 2023 /PRNewswire/ — Brace yourselves for a groundbreaking … Read more

A New Era Unveiled: Shlomi Nachman Joins Expanse Medical’s Board of Directors

August 21, 2023 by Allen Williams

Embarking on a Trail of Innovation: Shlomi Nachman Joins Expanse Medical’s Board of Visionaries PLEASANTON, Calif., Aug. 21, 2023 /PRNewswire/ — Expanse Medical, the trailblazing … Read more

A Triumph of Hope: European Medicines Agency Grants Green Light to Cellspan Esophageal Implant for Orphan Disease

August 21, 2023 by Allen Williams

In the heart of HOLLISTON, a tale of innovation unfolds on August 21, 2023. Enter Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a protagonist in … Read more

Nurami’s Breakthrough: FDA Grants Green Light to ArtiFascia® Dura Substitute

August 21, 2023 by Allen Williams

From the vibrant city of HAIFA, Israel, a groundbreaking saga unfolds on August 21, 2023. In a crescendo that resonates across borders, the stage belongs … Read more

Unlocking Hope: CRISPR’s Bold Steps in Battling Alzheimer’s, Navigating the Complex Path Ahead

August 21, 2023 by Allen Williams

At the forefront of scientific marvels stands CRISPR-Cas9, the very essence of gene-editing wizardry that earned Jennifer Doudna and Emmanuelle Charpentier the crown of Nobel … Read more

Breaking Boundaries: Regeneron’s Eylea Achieves High-Dose Approval, Unveiling an Expanded Horizon

August 21, 2023 by Allen Williams

In a game-changing move, the FDA has bestowed a new chapter upon Regeneron’s vision-transforming masterpiece, Eylea (aflibercept). A crescendo of innovation resonates as the label’s … Read more

Triumphant Resurgence: Roche and Exelixis’ Dynamic Drug Combo Achieves Remarkable Victory in Advanced Prostate Cancer Battle

August 21, 2023 by Allen Williams

In a groundbreaking twist, the powerful duo of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) has triumphed on a crucial battlefield. The pivotal Phase III … Read more

Dentsply Sirona Takes Center Stage: An Unmissable Presence at the Baird 2023 Global Healthcare Conference!

August 21, 2023 by Allen Williams

Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, is excited to announce its participation in the Baird 2023 Global Healthcare Conference. … Read more

FDA Chronicles: Unveiling the Latest Breakthroughs – August 18, 2023

August 21, 2023 by Allen Williams

Embarking on a Journey of Innovation: SILVER SPRING, Md., Aug. 18, 2023 /PRNewswire/ — Brace yourselves for a riveting revelation as the U.S. Food and … Read more

Ultragenyx’s Augmented Momentum: Unveiling Nasdaq Listing Rule 5635(c)(4) Inducement Grant – August 18, 2023

August 21, 2023 by Allen Williams

Ultragenyx Pharmaceutical Inc., a visionary biopharmaceutical firm committed to revolutionizing treatments for rare and ultra-rare ailments, has just unveiled an exciting development. In a bold … Read more

Exciting Boost for Iovance Biotherapeutics as Inducement Grants Unveiled under NASDAQ Listing Rule 5635(c)(4) on August 18, 2023

August 21, 2023 by Allen Williams

In a burst of exciting developments on August 18, 2023, SAN CARLOS-based powerhouse Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) unveiled its game-changing strides in the fight … Read more

Unveiling Dreams: Psychemedics Corporation Empowers with Inducement Grants – A Glimpse into August 18, 2023

August 21, 2023 by Allen Williams

With the tenacious energy of a decade-long journey, these options offer an exciting path forward, each bearing an exercise price of $4.65 per share, mirroring … Read more

A New Dawn for ALS Warriors: Mitsubishi Tanabe Pharma Canada Welcomes British Columbia’s Embrace of Innovative Oral Treatment in the Battle Against Amyotrophic Lateral Sclerosis

August 21, 2023 by Allen Williams

TORONTO, Aug. 18, 2023 /CNW/ – A Ray of Hope Pierces the Horizon: Mitsubishi Tanabe Pharma Canada (MTP-CA), a Proud Offspring of Mitsubishi Tanabe Pharma … Read more

Adapting to the Challenge: Pfizer and Moderna Unleash Upgraded COVID-19 Shots to Confront Evolving Variants

August 21, 2023 by Allen Williams

A Symphony of Defense Unveiled: Moderna Takes the Stage on Thursday, Revealing a Marvelous Revelation. Their Upgraded COVID-19 Warriors Rise, Crafting Shields of Neutralizing Antibodies … Read more

Breaking Ground in the Realm of Hope: Genethon’s Bold Gene Therapy Illuminates the Path with Early-Stage Triumphs Against a Rare Liver Disease

August 21, 2023 by Allen Williams

Defying the Shadows of Rare Liver Disease: Genethon’s Brave Journey into Gene Therapy Illuminates Hope for Crigler-Najjar Syndrome, as Promising Phase I/II Findings Grace the … Read more

Resignation Echoes: Kodiak CMO Exits Amidst Phase III Setback for Visionary Eye Therapy

August 21, 2023 by Allen Williams

A Curtain Call for Change: Kodiak Sciences’ Visionary Jason Ehrlich Bids Farewell as Chief Medical Officer and Chief Development Officer. The Countdown Begins as his … Read more

Major Breakthrough: Merck’s Welireg Triumphs in Phase III, Achieving Primary Goal in Battle Against Renal Cell Carcinoma

August 21, 2023 by Allen Williams

In a Thrilling Update, Merck’s Welireg (belzutifan) Smashes Expectations in Phase III LITESPARK-005 Trial. A Remarkable Leap Forward as Patients Battling Advanced Renal Cell Carcinoma … Read more

Navigating the Pulse of Progress: A Thrilling Week Unveils the Obesity Drug Race, Ipsen’s Long-Awaited Triumph, and More Unveiled Wonders

August 21, 2023 by Allen Williams

Igniting the Flames of the Weight-Loss Arena: Boehringer Ingelheim Emerges as the Trailblazer, Unveiling a Grand Plan for the Promising Obesity Drug Hope, Survodutide. In … Read more

Medical Marvel Unveiled: FDA Grants Approval to Regeneron’s Antibody for Extraordinary Hereditary Condition

August 21, 2023 by Allen Williams

A Historic Triumph: FDA’s Seal of Approval Graces Regeneron’s Veopoz, a Pioneer in CHAPLE Disease Battle—A Name Echoed by the Whispers of CD55-Deficient Protein-Losing Enteropathy. … Read more

Breaking News: FDA’s Spotlight Shines on Nefecon® as Calliditas Therapeutics Races Towards Full Approval, Guided by Everest Medicines’ Partnership

August 21, 2023 by Allen Williams

Shanghai, August 20, 2023 – In a Thrilling Symphony of Progress, Everest Medicines (HKEX 1952.HK) Takes Center Stage: The Grand News Unveiled – FDA’s Embrace … Read more

Bridging the Chasm: Championing Solutions for the UK’s Scientific Skills Dilemma

August 21, 2023 by Allen Williams

Emerging from the August’s Political Forge, a Resounding Pledge Echoes: Transform the UK into a ‘Scientific Superpower’, A Beacon of Opportunity Illuminating Every Nook. A … Read more

Bold FDA Pilot Sparks Debates: Revolutionizing Cancer Diagnostics Faces Skepticism

August 21, 2023 by Allen Williams

Embarking on a Bold Experiment, the FDA Initiates a Voluntary Pilot Program to Tackle the Unseen Perils of Greenlighting Precise Cancer Therapies Without Their Trusty … Read more

Unlocking the Potential of CRISPR: A Glimpse of Hope for Alzheimer’s Treatment Amidst Ongoing Challenges

August 21, 2023 by Allen Williams

Steering Toward Breakthroughs: CRISPR-Cas9, the Nobel Prize-Winning Genetic Marvel by Jennifer Doudna and Emmanuelle Charpentier, Nears its Debut in Alzheimer’s Clinical Trials. Yet, Amidst the … Read more

Surprising Twist: Hemlibra’s Clotting Incidents Outpace FVIII Alternatives 2.8 Times Over

August 18, 2023 by Allen Williams

Embarking on a Quest of Discovery, Unveiling from YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ — Brace yourselves for a groundbreaking revelation from the heart … Read more

Athersys, Inc. Unveils Exciting $3.5 Million Public Offering: Embarking on a New Financial Frontier

August 18, 2023 by Allen Williams

Thrilling Financial Venture Unfolds in Cleveland! In an electrifying move, Athersys, Inc. (Nasdaq: ATHX) has just unveiled its captivating “reasonable best efforts” public offering. Brace … Read more

Diving into the Future of Chewables: Procaps Group Unveils Trailblazing Gummy Tech in Captivating White Paper

August 17, 2023 by Allen Williams

Unveiling the Heat-Defying Marvel: Procaps Group Revolutionizes Gummies for a Seamless Journey MIAMI & BARRANQUILLA, Colombia–(BUSINESS WIRE) — Brace yourself for a game-changer in the … Read more

Urgent Call to Action: Reversal Needed on New Jersey’s Anti-Science “Equity Code” as Medical Experts Speak Out

August 17, 2023 by Allen Williams

TUCSON, Ariz., Aug. 16, 2023 (GLOBE NEWSWIRE) — Sparks fly as the battleground over education equity intensifies. In a razor-thin vote of 6 to 5 … Read more

Empowering Oncology Care in MENA: Fresh and Enhanced Resources Unveiled to Lead the Way

August 17, 2023 by Allen Williams

PLYMOUTH MEETING, Pa., Aug. 16, 2023 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®), a dynamic alliance of leading cancer centers, proudly unveils a wealth … Read more

Empower Your Workplace: The Art of Initiating Employee Resource Groups

August 17, 2023 by Allen Williams

Unlocking Unity and Success: The Power of Employee Resource Groups (ERGs) in Shaping Inclusive Workplaces. Discover how ERGs Drive Engagement, Retention, Recruitment, and Business Goals, … Read more

FDA Greenlights Delcath’s Innovative Cancer Drug-Device Combo: A Triumph of Tenacity after a Decade of Persistence!

August 17, 2023 by Allen Williams

FDA Greenlights Delcath Systems’ Hepzato Kit for Cutting-Edge Liver-Directed Treatment of Metastatic Uveal Melanoma, Culminating a Ten-Year Odyssey to Regulatory Approval Hepzato’s Unveiled Realm: Illuminating … Read more

Stada’s CEO Fuels Speculation: A Whirlwind of Buyout Rumors, a Potential $11B Prize in Play!

August 17, 2023 by Allen Williams

Intrigue Unveiled: Stada’s $11 Billion Puzzle of Possibility! Amidst the whispers of change, the stage is set for a monumental decision. Imagine a world where … Read more

Breaking Norms: Bluebird’s Lovo-Cel Sets Its Own Course with FDA Adcomm Bypass!

August 17, 2023 by Allen Williams

Plot Twist in Medical Saga: FDA Skips the Spotlight on bluebird bio’s Revolutionary Lovo-Cel Gene Therapy for Sickle Cell Disease! A Thrilling Quest: Lovo-Cel’s Destiny … Read more

Breaking Waves in Cancer Care: Seagen Unveils Phase III Triumph with Cutting-Edge Breast Cancer Combination Therapy!

August 17, 2023 by Allen Williams

Unlocking New Avenues in Cancer Battle: Brace yourself for a breakthrough unveiled by the biotech visionary, Seagen! With Wednesday’s dawn came a symphony of hope … Read more

Valneva Unveils Exciting News: Extending Current Loan Agreement for Continued Growth!

August 17, 2023 by Allen Williams

Up to an additional $100 million made available in two tranches Fueling Innovation from Saint-Herblain, France, August 17, 2023: Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a … Read more

Revolutionizing Labs: Roche Unveils CCM Vertical, a Game-Changer for Boosting Laboratory Efficiency!

August 17, 2023 by Allen Williams

Innovative Leap in Lab Tech! Roche’s Latest Breakthrough Unveiled in Basel, Switzerland — Introducing CCM Vertical, the Future of Sample Transportation. Say Goodbye to Conventional … Read more

Sonoma Pharmaceuticals Earns Prestigious Seal of Acceptance from National Eczema Association for Reliefacyn Advanced

August 16, 2023 by Allen Williams

BOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a pioneering force in global healthcare, harnessing the power of patented Microcyn® … Read more

Propanc Biopharma Embarks on Landmark First-In-Human Study Site for PRP at Renowned Peter Mac Cancer Center in Melbourne, Australia

August 16, 2023 by Allen Williams

MELBOURNE, Australia–(BUSINESS WIRE)– Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a pioneering biopharmaceutical powerhouse on a mission to revolutionize cancer treatment, has … Read more

Medicus IT Embraces a Bright Future with the Addition of Emily Sorrick as Chief People Officer, Bolstering its Dedication to Inclusive Excellence

August 16, 2023 by Allen Williams

ALPHARETTA, Ga., Aug. 15, 2023 /PRNewswire/ — Medicus IT, a pioneering force in healthcare technology solutions, is thrilled to unveil the arrival of Emily Sorrick … Read more

The Mosaic Company Unveils Mosaic Biosciences™ to Expand Offerings in Plant Health

August 16, 2023 by Allen Williams

TAMPA, Fla., Aug. 15, 2023 /PRNewswire/ — Igniting a Green Revolution, The Mosaic Company (NYSE:MOS) has unveiled the groundbreaking Mosaic Biosciences™ platform. This global initiative … Read more

Harmony Ventures Sets Sights on Rare Disease Breakthrough: Exploring $200M Zynerba Acquisition

August 16, 2023 by Allen Williams

Harmony Biosciences Makes Bold Move, Aims to Transform Portfolio: Enters Acquisition Talks with Zynerba Pharmaceuticals for Expansion into Rare Neuropsychiatric Disorders In a Strategic Move, … Read more

Design Therapeutics Faces a Rollercoaster Ride as Only Clinical Asset Undergoes Transformation, Sending Stock on a Tumultuous Plunge

August 16, 2023 by Allen Williams

Design Therapeutics Encounters a Twist in the Journey as Phase I Friedreich’s Ataxia Drug Hits a Bumpy Road with Injection Site Reactions. In a Strategic … Read more

FDA Clears the Path: Arcellx’s Multiple Myeloma Trial Resumes Amidst Shadows of a Patient’s Passing

August 16, 2023 by Allen Williams

Arcellx’s Triumph: Rekindling Hope for Multiple Myeloma Warriors. Against the Odds, iMMagine-1’s Phase II Journey Ignites Anew. Like a Phoenix Rising, FDA’s Greenlight Reignites Arcellx’s … Read more

Galecto’s Aspirations Take a Turn: Setback in Idiopathic Pulmonary Fibrosis Quest Leaves Hopeful Hearts Aflutter

August 16, 2023 by Allen Williams

The GALACTIC-1 Chronicles: Galecto’s Bold Journey Meets a Surprising Twist. Amid the Quest to Defy Fate, GB0139 Steps Forward as the Hopeful Hero. But Alas, … Read more

Breaking Barriers: Pfizer’s Bispecific Marvel Clinches FDA Accelerated Approval, Lighting the Path for Multiple Myeloma

August 16, 2023 by Allen Williams

FDA’s Green Light: Pfizer’s Game-Changing Bispecific, Elrexfio, Rockets Forward with Accelerated Approval to Combat Relapsed or Refractory Multiple Myeloma! Empowering Hope: Elrexfio’s Breakthrough Label Embraces … Read more

AN2 Therapeutics Lights Up the Financial Stage: Unveils $70.0 Million Pricing for Thrilling Underwritten Offering of Common Stock

August 16, 2023 by Allen Williams

Unveiling AN2 Therapeutics’ Triumph: A Bold Step Forward! From the Heart of Silicon Valley Emerges a Powerhouse, AN2 Therapeutics, Inc. (Nasdaq: ANTX). Guided by the … Read more

Biophytis Charts Path Forward: Exciting Regulatory Moves for COVA Project Unveiled Across Europe and the United States

August 16, 2023 by Allen Williams

Crossing Borders, Bridging Health: Biophytis Forges Ahead! Paris and Cambridge Align as Biophytis Unveils Regulatory Momentum for COVA Project. Empowered by EMA and FDA Insights, … Read more

Empower Your Workplace: A Guide to Launching Your Own Employee Resource Group!

August 16, 2023 by Allen Williams

Unlocking the Power of Unity: The Impactful Role of Employee Resource Groups (ERGs) in Cultivating Inclusive Workspaces. Discover How ERGs Drive Employee Engagement, Retention, Recruitment, … Read more

Revolutionizing Genetic Medicine: GeneFab Launches to Provide Cutting-Edge Manufacturing and Synthetic Biology Design Services

August 11, 2023 by Allen Williams

With its cutting-edge cGMP facility in San Francisco Bay Area, GeneFab is ready to take on new customers, offering expertise in complex cell and gene … Read more

Second Quarter 2023 Financials: Seeing Bright Earnings Growth at Comeera Life Sciences

August 11, 2023 by Allen Williams

We are proud to announce that Comera has advanced to the final stage of technical evaluation in its research collaboration with Regeneron, a top biotechnology … Read more

Bristol Myers Squibb Soars Into Billion Dollar Roundtable, Elevating Supplier Diversity Initiatives

August 11, 2023 by Allen Williams

Reaching new heights, we’ve achieved our goal of investing $1 billion in diverse-owned suppliers – and we’re not stopping there! Our commitment to this important … Read more

Breakthrough Heart Failure Treatment Tested Successfully with Daxor BVA-100®: JACC-HF Reports Amazing Results

August 11, 2023 by Allen Williams

In a major step towards advancing precision healthcare and medical treatments, global biotechnology company Rakuten Medical, Inc. has entered into an exclusive licensing and commercialization … Read more

Revolutionary Heart Failure Treatment Using Daxor BVA-100® Successfully Tested in JACC-HF Trials!

August 11, 2023 by Allen Williams

Daxor Corporation, an innovative leader in blood volume measurement technology, recently published a research paper in the Journal of the American College of Cardiology – … Read more

Biopharma Seeks Superior Talent in Response to Unprecedented Demand Following the Pandemic

August 11, 2023 by Allen Williams

Despite an uncertain political climate and global economic trends, the job market in the US is still soaring. The unemployment rate currently sits at a … Read more

J&J’s Revolutionary New Treatment for Multiple Myeloma Gets the Green Light from the FDA

August 11, 2023 by Allen Williams

J&J takes the fast lane to cancer treatment! Its new drug, a bispecific antibody, has been granted accelerated approval from the Food and Drug Administration … Read more

FDA Rejection Leaves Galera Devastated, Forced to Lay Off 70% of Employees

August 11, 2023 by Allen Williams

The FDA dealt a crushing blow to Galera Therapeutics Wednesday, rejecting its proposed treatment for radiotherapy-induced severe oral mucositis in patients with head and neck … Read more

Illumina’s Struggles Continue with Lower Outlook and Executive Exits

August 11, 2023 by Allen Williams

Illumina recently revealed that its expected revenue growth for FY2023 has dropped drastically from an initial forecast of 7-10%, to now just a 1% increase. … Read more

Novo Nordisk Invests Heavily in the Fight Against Obesity with $1 Billion Acquisition of Inversago

August 11, 2023 by Allen Williams

In a move that further betters its already vast obesity and diabetes portfolio, Novo Nordisk on Thursday staked over $1 billion on the acquisition of … Read more

Mirum Pharmaceuticals Awards New Incentive Grants – Unlocking Possibilities to Achieve Nasdaq Listing Success!

August 11, 2023 by Allen Williams

Mirum Pharmaceuticals, Inc. welcomed six new employees to the team on August 10, 2023, with special inducement awards to show appreciation. The awards include non-qualified … Read more

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

August 11, 2023 by Allen Williams

Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) announced today its plans to release its second quarter 2023 financial results on Monday, August 14, … Read more

Generic Drug Market on the Rise as China Pharma’s Candesartan Hypertension Product Passes Tough Consistency Evaluation

August 10, 2023 by Allen Williams

China Pharma Holdings, Inc. (NYSE American: CPHI), a leading specialty pharmaceutical company, is delighted to announce the successful approval for its candesartan tablets from the … Read more

T2 Biosystems Reclaims Position of Compliance with Nasdaq’s Market Value Requirement

August 10, 2023 by Allen Williams

On August 8, 2023, T2 Biosystems, Inc (NASDAQ:TTOO) received notice from the NASDAQ Stock Market LLC that its market value of listed securities was once … Read more

Inteleos Launches Point of Care Ultrasound Certification Academy with Jasmine Rockett at the Helm

August 10, 2023 by Allen Williams

Inteleos, a leading non-profit global healthcare certification organization, is pleased to announce the newest addition to their team – Jasmine Rockett. In her new role … Read more

Bio Company Soars to Success in First Half of 2023!

August 10, 2023 by Allen Williams

Form Bio, the game-changing AI-enabled drug finding platform, proudly shared its noteworthy accomplishments and significant product advancements for the first half of this year. With … Read more

Takeda’s Denali Fails Initial Alzheimer’s Drug Trials — Possible Unwieldy Treatment Uncovered

August 10, 2023 by Allen Williams

After studying the initial Phase I findings of an experimental Alzheimer’s therapy, Takeda and Denali Therapeutics have concluded that the treatment had a “narrow therapeutic … Read more

Bluebird Ventures into Uncharted Waters as FDA Decision, Zynteglo Uptake Looms Large Despite Cash Crunch

August 10, 2023 by Allen Williams

Despite the hampered state of its finances, bluebird bio remains steadfast in its operations through the end of 2021. Massachussetts-based gene therapy company announced the … Read more

Novartis Reaches Milestone in Chronic Hives Treatment as Sanofi Poses a Threat

August 10, 2023 by Allen Williams

Novartis has just made a giant leap forward in its quest to become a leader in the chronic spontaneous urticaria market. On Thursday, the Swiss … Read more

Regeneron Investing Heavily in Gene Therapies for Hearing Loss – $109M Deal

August 10, 2023 by Allen Williams

Regeneron Pharmaceuticals, a New York-based biotech, is investing in its long-term partnership with Decibel Therapeutics with the purchase of the company for $109 million. The … Read more

Mirati CEO Takes Battleground Stance Against Amgen, Bows Out From KRAS Race

August 10, 2023 by Allen Williams

Mirati Therapeutics set a course for a new leadership chapter on Tuesday, with founder and president Charles Baum taking the reins of the company while … Read more

FDA’s OTP Super Office Set to Take on 500 Jobs!

August 10, 2023 by Allen Williams

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research (CEBR), is confident in the OTP’s progress towards filling their 500 vacancies. He … Read more

Wegovy Protects Cardiovascular Health in Overweight and Obese Adults: A Gift for Good Health!

August 9, 2023 by Allen Williams

Novo Nordisk’s Wegovy (semaglutide) has achieved its primary efficacy standard in the Phase III SELECT study, showing a robust effect on cardiovascular well-being in overweight … Read more

Novavax Profits Soar as Vaccine Hopes Hang on Updated COVID Shot!

August 9, 2023 by Allen Williams

Novavax, the embattled vaccine maker, scored a surprising victory this week, announcing $58 million in net income for the second quarter of the year—a major … Read more

Mirati Therapeutics Sees Overwhelming Demand with Expansion of Public Offering – August 09, 2023

August 9, 2023 by Allen Williams

Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, announced the pricing of an underwritten public offering of 9,669,631 shares of common stock at … Read more

First Patient Enrolled in Japan for Groundbreaking Clinical Trial of Leniolisib for APDS Treatment!

August 9, 2023 by Allen Williams

Pharming Group N.V. is pleased to announce that the first patient has successfully been enrolled in its groundbreaking Phase III clinical trial to evaluate leniolisib … Read more

Novozymes Delivers Impressive Results in First Half of 2023, Narrowly Adjusting Full Year Outlook

August 9, 2023 by Allen Williams

Novozymes has delivered an impressive 3% organic sales growth, despite a turbulent environment. The full-year organic sales growth outlook for 2023, however, has been slightly … Read more

SK bioscience Boosts Strategic Alliance with Novavax through Equity Investment

August 9, 2023 by Allen Williams

SK bioscience is taking the fight against the COVID-19 pandemic to the next level with a strategic equity investment into Novavax to bolster their partnership … Read more

GeneDx Grants Redefining Nasdaq Listing Rules – How It Could Impact Investors

August 9, 2023 by Allen Williams

GeneDx, an innovator in delivering improved health solutions through genetic and clinical knowledge, today announced that it has granted new employees 23,769 restricted stock units … Read more

Benitec Biopharma Inc. Secures Major Funding with $30 Million Underwritten Public Offering

August 9, 2023 by Allen Williams

Benitec Biopharma Inc. (Nasdaq: BNTC) is delighted to announce the pricing of its underwritten public offering, comprising 15,544,041 shares of its common stock, along with … Read more

House Dems Take Legal Action to Expand Scope of IRA Battle

August 9, 2023 by Allen Williams

In response to the looming threat of price-negotiating by the federal government, major biopharmaceutical companies have begun to abandon costly drug programs. This has provoked … Read more

Biologics: Unanticipated Challenges Created by JIRA

August 9, 2023 by Allen Williams

Despite initial impressions, experts warn the Inflation Reduction Act may not be good news for biological products after all, given their past performance in the … Read more

BIGT Biopharma Sees Record-Breaking Q2 2023 Financials

August 8, 2023 by Allen Williams

GT Biopharma, Inc., an immuno-oncology firm pioneering revolutionary treatments utilizing its TriKE® platform, has released its second quarter 2023 financial data for the period of … Read more

Keros Therapeutics Reaps Impressive Q2 2023 Financials and Business Milestones!

August 8, 2023 by Allen Williams

Keros Therapeutics, Inc. (KROS) revealed its financial results for the quarter ended June 30th, 2023 along with delivering a comprehensive business update. The clinical-stage biopharmaceutical … Read more

Kytopen Welcomes Michael Chiu, Ph.D., as Its New Chief Executive Officer

August 8, 2023 by Allen Williams

Kytopen, a biotechnology company at the forefront of advanced cell engineering solutions, has announced the appointment of Michael Chiu, Ph.D., as its Chief Executive Officer. … Read more

Vincerx Pharma Celebrates Notable Q2 2023 Results and Updates on Corporate Progress

August 8, 2023 by Allen Williams

Vincerx Pharma Inc. (Nasdaq: VINC), a pioneering biopharmaceutical company striving to improve the lives of cancer patients by providing innovative treatments, announced its financial results … Read more

Unlocking the Potential of CBD: Life Sciences Sets Out to Improve Oral Uptake Through Clinical Pharmacology Study

August 8, 2023 by Allen Williams

180 Life Sciences Corp. (NASDAQ: ATNF) has recently struck a deal with Prof. Avi Domb from Hebrew University’s School of Pharmacy and Prof. Elyad Davidson … Read more

Voyager Therapeutics Welcomes Beth Shafer as Chief Business Officer: Expertise to Accelerate Innovation

August 8, 2023 by Allen Williams

Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as their new Chief Business Officer (CBO). Shafer brings more … Read more

Bavarian Nordic’s Chikungunya Vaccine Shows Promising Results in Second Phase III Trial

August 8, 2023 by Allen Williams

The race to create a successful chikungunya vaccine is intensifying, after Danish biotech Bavarian Nordic announced promising Phase III trial results for its vaccine candidate—marking … Read more

Novartis’ Hopes to Treat Sickle Cell Sufferers Dashed by EU Reversal

August 8, 2023 by Allen Williams

Novartis’ much-hyped sickle cell disease therapy Adakveo (crizanlizumab) has received a stunning blow, as the European Commission has officially withdrawn its conditional marketing authorization. The … Read more

Lilly’s Missteps Revealed: Rezpeg Atopic Dermatitis Trials Show Flawed Miscalculations

August 8, 2023 by Allen Williams

Nektar Therapeutics made an unexpected announcement on Monday – its investigational regulatory T-cell stimulator rezpegaldesleukin (rezpeg) has not been delivering the efficacy data as expected. … Read more

Navigating Challenges: Sage Reports Difficult Decisions Post Zuranolone Rejection for Major Depressive Disorder Treatment

August 8, 2023 by Allen Williams

Sage Therapeutics’ stock took a hard nosedive on Monday, dropping 46%, after the Food and Drug Administration (FDA) issued a Complete Response Letter regarding their … Read more

A Potential Breakthrough for Breast Cancer: Anixa Biosciences Begins Enrollment for Keytruda® Vaccine Clinical Trial

August 7, 2023 by Allen Williams

Anixa Biosciences, Inc. (NASDAQ: ANIX) has welcomed a significant milestone in the fight against breast cancer, with partner Cleveland Clinic launching a treatment arm for … Read more

$75 Million Investment Jeopardize to Revolutionize Cancer Diagnostics with AIMIO Biotech, Inc.

August 7, 2023 by Allen Williams

IO Biotech, Inc. (Nasdaq: IOBT) announced today that it has entered into a definitive securities purchase agreement for a private placement, garnering a total of … Read more

Oragenics Seeks to Raise Funds Through Private Placement

August 7, 2023 by Allen Williams

Oragenics Inc., a biotech company focused on combating infectious diseases, including those caused by coronaviruses, is thrilled to announce that two healthcare-focused investors have entered … Read more

GERO and FOXO Technologies™ Unite in Joint Venture to Find Out How Artificial Intelligence and Epigenetics Can Bolster Human Longevity

August 7, 2023 by Allen Williams

GERO, a notable AI-driven biotechnology company dedicated to extending life expectancy, and FOXO Technologies Inc., a pioneering epigenetic biomarker explorer and marketer, have announced the … Read more

Rhythm Pharmaceuticals Gives French Patients with Hypothalamic Obesity Pre-Marketing Early Access to Setmelanotide

August 7, 2023 by Allen Williams

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is delighted to announce that the French National Agency for Medicines and Health Products Safety (ANSM) and French National Authority … Read more

Astellas Invests in Life-Changing Therapies from Poseida, Offering New Hope for Patients

August 7, 2023 by Allen Williams

Poseida Therapeutics, Inc., a groundbreaking clinical-stage cell and gene therapy company, recently received a $50 million boost from strategic investor Astellas Pharma US, Inc. in … Read more

Breakthrough Treatment for Duchenne Muscular Dystrophy Gets FDA Orphan Drug Designation

August 7, 2023 by Allen Williams

NS Pharma, Inc. today announced an incredible breakthrough for patients with Duchenne muscular dystrophy: The U.S. Food and Drug Administration (FDA) has granted Orphan Drug … Read more

Uncovering New Hope: Advancing Treatment Options for Those Living with Rare Cardiovascular Disease.

August 7, 2023 by Allen Williams

The potential for the pulmonary arterial hypertension treatments market is huge, with estimates of nearly $11 billion by 2030 – significantly more than the projected … Read more

Novartis’ Groundbreaking Sickle Cell Disease Drug Loses EU Support

August 7, 2023 by Allen Williams

The European Commission has officially withdrawn its approval of Novartis’ treatment for sickle cell disease, Adakveo (crizanlizumab). The Swiss pharmaceutical behemoth announced the government’s reversal … Read more

Astellas Gets Life-Changing FDA Approval for Iveric in Treating Geographic Atrophy

August 7, 2023 by Allen Williams

Iveric Bio’s cutting-edge intravitreal avacincaptad pegol is now officially available as Izervay, after it just received the FDA’s stamp of approval. This groundbreaking medication is … Read more

Second Quarter 2023: Protera Therapeutics Reaches Financial Milestone and Highlights Business Update

August 4, 2023 by Allen Williams

Protara Therapeutics, Inc. (Nasdaq: TARA) announced financial results and an update on its progress for the second quarter of 2023 on August 03. Protara is … Read more

Ginkgo Bioworks Launching Pioneering Biosecurity Partnership with the Government of Panama!

August 4, 2023 by Allen Williams

Today Ginkgo Bioworks (NYSE: DNA) and the Government of the Republic of Panama’s Gorgas Memorial Institute for Health Studies have joined forces in a groundbreaking … Read more

Unlocking Medicare’s Potential Savings: How AIRA’s Drug Price Negotiation Program Could Save Billions in its First Year

August 4, 2023 by Allen Williams

According to a recent research brief published in the Journal of Managed Care & Specialty Pharmacy, Medicare could be set to save a colossal sum … Read more

GLP-1 Drugs: The Latest Breakthrough in Treating Alcohol and Opioid Addiction?

August 4, 2023 by Allen Williams

A potential revolutionary trifecta of weight loss and type 2 diabetes treatments, glucagon-like peptide-1 receptor agonists have been garnering much attention lately. Not only may … Read more

Breakthrough: FDA Approves Taiho’s Lonsurf for Treatment of Metastatic Colorectal Cancer, Outpacing Takeda and Hutchmed!

August 4, 2023 by Allen Williams

The FDA has given the green light to Taiho Oncology’s Lonsurf (tipiracil) to be used in tandem with Roche’s Avastin (bevacizumab) as an effective treatment … Read more

Regeneron Ready for Speedy FDA Approval on Higher-Strength Eylea Eye Treatment

August 4, 2023 by Allen Williams

Regeneron made a surprise announcement on Thursday that the FDA was poised to make a decision on a higher dose regimen of Eylea (aflibercept) in … Read more

Moderna Boosts COVID-19 Vaccine Forecast Despite Q2 Revenue Plunge

August 4, 2023 by Allen Williams

Moderna is fighting back against the impacts of the pandemic, increasing research and development spending despite a dip in revenue. The mRNA biotech released its … Read more

Basilea Submits Groundbreaking NDA for Innovative Antibiotic Ceftobiprole to FDA

August 4, 2023 by Allen Williams

We seek approval for three bacterial infections: Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). These … Read more

Unprecedented Move: US FDA Gives Mesoblast the Go-Ahead For Children’s Graft Versus Host Disease Therapy

August 4, 2023 by Allen Williams

Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, just received a complete response from the US Food and Drug Administration (FDA) … Read more

New Gene Therapies Could Transform Heart Disease Treatment: Evox Therapeutics Joins Forces to Push AAV-Exosome Delivery to the Next Level

August 4, 2023 by Allen Williams

This ground-breaking agreement seeks to tackle the difficult and long-standing issues surrounding cardiovascular disease. It is aimed at finding effective ways to combat this life-threatening … Read more

ImmPrev Bio, Inc. Unveils Breakthrough Diagnostic and Early Treatment for Crohn’s Disease!

August 3, 2023 by Allen Williams

Bio, Inc. has been granted an exclusive license to bring to market an innovative diagnostic tool and a promising early-stage treatment for Crohn’s disease. This … Read more

Spectacular Financial Success in Q2 2023: An Insider’s Look at Specimen Reports’ Results

August 3, 2023 by Allen Williams

iSpecimen Inc (Nasdaq: ISPC) announced its financial and operating results for the second quarter of 2023, which ended June 30th. The healthcare specimen provider and … Read more

Editas Medicine Reports Impressive Q2 2023 Results and News

August 3, 2023 by Allen Williams

Cambridge, Mass.-based Editas Medicine, Inc. (Nasdaq:EDIT) reported its second quarter 2023 financial results, sharing progress on its clinical-stage gene-editing efforts as well as updates on … Read more

Unlocking the Potential of Biotech: Is the Cold Spell Fading?

August 3, 2023 by Allen Williams

Biotech stocks have endured a punishing bear market for what seems to be an eternity, making it one of the worst periods on record for … Read more

FDA Takes Action Against Cancer Drug Maker Intas: Warning Letter Issued

August 3, 2023 by Allen Williams

The US Food and Drug Administration (FDA) has raised serious concerns about the quality control practices at Intas Pharmaceuticals’ plant in Sanand, India, going so … Read more

Illumina and Guardant Strengthen Partnership and Put Legal Dispute Behind Them

August 3, 2023 by Allen Williams

Illumina and Guardant Health are now ready to put the past behind them as they agreed to cease trade secrets litigation. They are now looking … Read more

Explosive Trikafta Demand Skyrockets Cystic Fibrosis Sales: Vertex Revises Forecast Upward

August 3, 2023 by Allen Williams

Vertex Pharmaceuticals has experienced an upsurge in demand for Trikafta, resulting in a 14% surge in product revenues in the second quarter – a development … Read more

Battle of the Pharmaceutical Giants: GSK Suing Pfizer for Alleged RSV Vaccine IP Violations

August 3, 2023 by Allen Williams

On Wednesday, GlaxoSmithKline embarked on an epic legal battle against pharmaceutical giant Pfizer, claiming four breaches of their patents regarding the antigen used in their … Read more

From Battlefield to Lab Bench: Leveraging Military Service to Forge a Career in Pharma

August 3, 2023 by Allen Williams

Every year, hundreds of thousands of US veterans are transitioning from their military life to civilian life. The journey of finding a place in the … Read more

Biotechs’ Career Sites: Uncovering Room for Improvement

August 3, 2023 by Allen Williams

Although layoffs are still an all too familiar reality, the demand for talented individuals in the biotech industry has never been higher. Emerging biotechs are … Read more

Biopharma Mergers: What the FTC’s New Guidelines Could Mean for the Industry

August 2, 2023 by Allen Williams

Last month, the U.S. Federal Trade Commission took a bold step in their efforts to regulate the biopharmaceutical industry, introducing new draft merger guidelines. The … Read more

Experience Stellar Results: Novavax to Host Call about Q2 2023 Financial Highlights & Updates on August 8

August 2, 2023 by Allen Williams

Novavax, Inc. (Nasdaq: NVAX), a pioneering player in the protein-based vaccines space with its Matrix-M™ adjuvant, is excited to announce that it will report its … Read more

FDA Grants Orphan Drug Status to TYRA-300: A Promising Treatment for Achondroplasia

August 2, 2023 by Allen Williams

Today, Tyra Biosciences, Inc. (Nasdaq: TYRA), a California-based clinical-stage biotechnology company that’s developing cutting-edge precision medicines targeting large opportunities in Fibroblast Growth Factor Receptor (FGFR) … Read more

MEKanistic Therapeutics Innovative Cancer Treatment Candidate to Receive Funding for Further Development from the National Cancer Institute!

August 2, 2023 by Allen Williams

The NExT Program is on a mission to revolutionize clinical practices and treatments for cancer patients. This unique translational research undertaking seeks to develop promising … Read more

FDA Approves RevBio’s Second U.S. Clinical Trial for Advanced Dental Implant Stabilization

August 2, 2023 by Allen Williams

RevBio, Inc. is thrilled to announce that it has been granted approval from the U.S. Food and Drug Administration for a 20-patient clinical trial to … Read more

AltruBio’s Potential Game Changer for Ulcerative Colitis Treatment Proved in Positive Phase 1 Clinical Trial

August 2, 2023 by Allen Williams

AltruBio Inc., a biotech company revolutionizing the treatment of immune-related diseases, has announced hugely encouraging topline results from its first clinical trial of its subcutaneous … Read more

Vanquish Minimally Invasive Prostate Cancer Therapy Achieves U.S. FDA Breakthrough Device Designation with Francis Medical

August 2, 2023 by Allen Williams

Francis Medical, Inc., a privately held medical device company, is celebrating a major milestone – the U.S. Food and Drug Administration (FDA) has granted Breakthrough … Read more

Older posts
Page1 Page2 … Page5 Next →
©2023